Luminex (LMNX) 10-K 26 Feb 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Entity [Abstract]
Entity Registrant Name	Luminex Corp
Entity Central Index Key	1,033,905
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		44,124,802
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 867,659,303

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 127,112	$ 93,452
Accounts receivable (net of allowance for doubtful accounts of $1,345 and $419 at December 31, 2017 and 2016, respectively)	40,648	32,365
Inventories, net	49,478	40,775
Prepaids and other	7,403	7,145
Total current assets	224,641	173,737
Property and equipment, net	58,258	57,375
Intangible assets, net	75,985	84,841
Deferred income taxes	37,552	42,497
Goodwill	85,481	85,481
Other	8,599	6,785
Total assets	490,516	450,716
Current liabilities:
Accounts payable	14,537	12,276
Accrued liabilities	25,990	22,804
Deferred revenue	4,721	5,120
Total current liabilities	45,248	40,200
Deferred revenue	1,498	1,875
Other	5,863	4,962
Total liabilities	52,609	47,037
Stockholders' equity:
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 43,404,493 shares at December 31, 2017; 42,802,480 shares at December 31, 2016	43	43
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	350,834	336,430
Accumulated other comprehensive loss	(625)	(1,692)
Retained earnings	87,655	68,898
Total stockholders' equity	437,907	403,679
Total liabilities and stockholders' equity	$ 490,516	$ 450,716

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Allowance for doubtful accounts	$ 419	$ 204
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	42,802,480	42,314,581
Common stock, outstanding (in shares)	42,802,480	42,314,581
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Common Stock, Dividends, Per Share, Declared	$ 240	$ 0	$ 0
Revenue	$ 306,571	$ 270,639	$ 237,708
Cost of revenue	107,525	90,984	69,001
Gross profit	199,046	179,655	168,707
Operating expenses:
Research and development	45,717	48,659	42,690
Selling, general and administrative	107,322	99,511	84,760
Amortization of acquired intangible assets	8,854	8,218	3,900
Restructuring Charges	0	2,281	0
Total operating expenses	161,893	158,669	131,350
Income from operations	37,153	20,986	37,357
Other (expense) income, net	(4)	129	987
Gain (Loss) on Extinguishment of Debt	0	(1,500)	0
Settlement of litigation, net	0	0	(5,300)
Income before income taxes	37,149	19,615	33,044
Income tax (expense) benefit	(7,726)	(5,801)	3,817
Net income	29,423	13,814	36,861
Net Income (Loss) Available to Common Stockholders, Basic	28,894	13,814	36,861
Net Income (Loss) Attributable to Parent, Diluted	28,894	13,814	36,861
Foreign currency translation adjustments	1,067	(434)	(531)
Dividends declared per share	0	38	(21)
Other comprehensive income:	1,067	(396)	(552)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 30,490	$ 13,418	$ 36,309
Net income per share, basic (in dollars per share)	$ 0.67	$ 0.32	$ 0.88
Shares used in computing net income per share, basic (in shares)	43,173	42,584	42,091
Net income per share, diluted (in dollars per share)	$ 0.67	$ 0.32	$ 0.86
Shares used in computing net income per share, diluted (in shares)	43,300	43,013	42,637

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ 29,423	$ 13,814	$ 36,861
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,641	20,131	13,744
Stock-based compensation	12,478	11,821	10,855
Deferred income tax (benefit) expense	6,383	3,626	(5,624)
Excess income tax benefit from employee stock-based awards	0	0	(10)
Loss on sale of assets	964	265	385
Other	1,531	(1,378)	(252)
Changes in operating assets and liabilities:
Accounts receivable, net	(8,265)	1,136	(594)
Inventories, net	(8,668)	(5,484)	5,476
Other assets	(83)	1,811	(968)
Accounts payable	1,798	3,460	(3,943)
Accrued liabilities	(2,657)	198	1,879
Dividends	2,671	0	0
Deferred revenue	(785)	281	(427)
Net cash provided by operating activities	57,431	49,681	57,382
Cash flows from investing activities:
Purchases of available-for-sale securities	0	0	(7,488)
Sales and maturities of available-for-sale securities	0	19,491	4,000
Purchase of property and equipment	(14,635)	(13,130)	(18,706)
Payments to Acquire Businesses, Net of Cash Acquired	0	68,098	0
Payments to Acquire Other Investments	1,000	1,000	0
Proceeds from sale of assets and investments	62	45	893
Acquired technology rights	(140)	(200)	(852)
Net cash used in investing activities	(17,113)	(62,892)	(22,153)
Increase (Decrease) in Notes Receivables	1,400	0	0
Cash flows from financing activities:
Payments on debt	0	(25,000)	0
Proceeds from employee stock plans and issuance of common stock	4,305	5,089	3,118
Payments for stock repurchases	(2,350)	(1,719)	(1,603)
Excess income tax benefit from employee stock-based awards	0	0	10
Payments of Ordinary Dividends	(7,930)	0	0
Net cash (used in) provided by financing activities	(5,975)	(21,630)	1,525
Effect of foreign currency exchange rate on cash	(683)	(253)	98
Change in cash and cash equivalents	33,660	(35,094)	36,852
Cash and cash equivalents, beginning of year	93,452	128,546	91,694
Cash and cash equivalents, end of year	$ 127,112	$ 93,452	$ 128,546

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss)	(Accumulated Deficit) Retained Earnings
Balance (in shares) at Dec. 31, 2014		41,805,962
Balance at Dec. 31, 2014	$ 319,994	$ 42	$ 309,424	$ (744)	$ 11,272
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		128,751
Exercise of stock options	1,878	$ 0	1,878	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)		300,733
Issuances of restricted stock, net of shares withheld for taxes	(1,604)	$ 0	(1,604)	0	0
Stock compensation	10,827	$ 0	10,827	0	0
Issuance of common shares under ESPP (in shares)		79,135
Issuance of common shares under ESPP	1,122	$ 0	1,122	0	0
Net income	36,861	0	0	0	36,861
Tax benefits associated with options		0	10	(16)	0
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation	(6)
Foreign currency translation adjustments	(531)	$ 0	0	(531)	0
Other (in shares)		0
Other	(5)	$ 0	0	(5)	0
Balance (in shares) at Dec. 31, 2015		42,314,581
Balance at Dec. 31, 2015	368,536	$ 42	321,657	(1,296)	48,133
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		178,111
Exercise of stock options	3,303	$ 0	3,303	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)		228,480
Issuances of restricted stock, net of shares withheld for taxes	(1,718)	$ 0	(1,718)	0	0
Stock compensation	11,776	$ 0	11,776	0	0
Issuance of common shares under ESPP (in shares)		81,308
Issuance of common shares under ESPP	1,413	$ 0	1,413	0	0
Net income	13,814	0	0	0	13,814
Tax benefits associated with options	6,951	0	0	0	6,951
Foreign currency translation adjustments	(434)	$ 0	0	(434)	0
Other (in shares)		0
Other	$ 38	$ 0	0	38	0
Balance (in shares) at Dec. 31, 2016	42,314,581	42,802,480
Balance at Dec. 31, 2016	$ 403,679	$ 42	336,431	(1,692)	68,898
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		163,579
Exercise of stock options	2,684	$ 0	2,684	0	0
Issuances of restricted stock, net of shares withheld for taxes (in shares)		345,978
Issuances of restricted stock, net of shares withheld for taxes	(2,349)	$ (1)	(2,350)	0	0
Stock compensation	12,409	$ 0	12,409	0	0
Issuance of common shares under ESPP (in shares)		92,456
Issuance of common shares under ESPP	1,591	$ 0	1,591	0	0
Net income	29,423	0	0	0	29,423
Foreign currency translation adjustments	1,067	$ 0	0	1,067	0
Other (in shares)		0
Other		$ 0		0
Dividends, Common Stock, Cash	$ (10,597)		69		(10,666)
Balance (in shares) at Dec. 31, 2017	42,802,480	43,404,493
Balance at Dec. 31, 2017	$ 437,907	$ 43	$ 350,834	$ (625)	$ 87,655

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company's proprietary technologies. Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company's end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. The Company primarily serves the diagnostics, pharmaceutical and research industries by marketing products, including the Company's specific testing equipment and assays, to various types of testing laboratories. The Company has a large base of installed systems that has grown primarily from the following: • placements made by customers within the Company's Licensed Technologies Group (LTG), previously referred to as the Company's "Partner Business," which customers either: • license the Company's xMAP technology and develop products that incorporate the Company's xMAP technology into products that they then sell to end users, or • purchase the Company's proprietary xMAP laboratory instrumentation and the Company's proprietary xMAP microspheres and sell xMAP-based assay products and/or xMAP-based testing services, which run on the xMAP instrumentation, and pay a royalty to the Company; • In addition, the Company utilizes a direct sales force that focuses on the sale of molecular diagnostic assays that run on the Company's systems. As of December 31, 2017 , the Company had 73 strategic partners, 53 of which have released commercialized reagent-based products utilizing the Company's technology. Luminex and these partners have sold approximately 14,848 xMAP-based instruments in laboratories worldwide as of December 31, 2017 . The Company's remaining partners are in various stages of development and commercialization of products incorporating our technology. A primary focus for the Company's growth is the development and sale of molecular diagnostic assays utilizing the Company's proprietary MultiCode ® and VERIGENE technologies for use on the Company's installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company's increasing installed base of instruments. Luminex's assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex's assay products are currently focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements. Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased. Investments The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates fair value of these investments. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity. Marketable securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date. The fair value of all securities is determined by obtaining non-binding market prices from the Company's third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings. Fair Value of Financial Instruments The fair values of financial instruments are determined by obtaining non-binding market prices from the Company's third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, cost-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2017 and 2016 . See Note 6 for further details concerning fair value measurements. Supplemental Cash Flow Statement Information (in thousands) Year Ended December 31, 2017 2016 2015 Cash paid during the period for taxes $ 1,393 $ 385 $ 578 Cash (received) paid during the period for interest and penalties 57 (3 ) 96 Cash paid during the period for Nanosphere debt interest — 391 — Cash paid during the period for Nanosphere debt prepayment penalty — 1,500 — Effect of acquisitions: Fair value of tangible assets acquired — 34,372 — Liabilities assumed — (25,391 ) — Cost in excess of fair value of assets acquired — 35,862 — Acquired identifiable intangible assets — 27,595 — Deferred tax assets, net — 6,989 — In-process research and development — 12,982 — Total purchase price — 92,409 — Less cash and cash equivalents acquired — 24,311 — Net cash paid for business acquisition $ — $ 68,098 $ — Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company’s short-term investments consist of investments in high credit quality financial institutions, non-government sponsored debt securities and corporate issuers. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral. Laboratory Corporation of America (LabCorp) accounted for 20% , 20% and 24% of our total revenues in 2017 , 2016 and 2015 , respectively. Thermo Fisher Scientific Inc. accounted for 15% , 13% and 13% of our total revenues in 2017 , 2016 and 2015 , respectively. No other customer accounted for more than 10% of our total revenues in 2017 , 2016 or 2015 . Inventories Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company's markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company's policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company's assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company's estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be overvalued, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company's operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value. Property and Equipment Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex xMAP, ARIES ® and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as "Assets on loan/rental." Goodwill and Other Intangible Assets Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, using a two-step impairment process tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2017 . In 2017 and 2016 , the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company's annual test did not result in an impairment charge in 2017 , as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2017 , 2016 or 2015 . Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made. Revenue Recognition and Allowance for Doubtful Accounts Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company's systems. The Company recognizes product revenue at the time the product is shipped provided there is persuasive evidence of an agreement, no right of return exists, the fee is fixed or determinable and collectability is probable. There is no customer right of return in the Company’s sales agreements. If the criteria for revenue recognition are not met at the time of shipment, the revenue is deferred until all criteria are met. The Company may enter into arrangements for system sales that are multiple-element arrangements, including services such as installation and multiple products. When such arrangements include installation, no revenue is generally recognized until installation and delivery is complete. When such arrangements include multiple products, all of the products are generally shipped at the same time. As a result, the Company generally does not need to defer revenue for any undelivered elements. However, in situations where revenue is deferred for an undelivered element, the Company has typically been able to determine the selling price of each deliverable in a multiple-element arrangement based on the price for such deliverable when it is sold separately. The Company provides systems and certain other hardware to customers through reagent rental agreements under which the customers commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for diagnostic assays and other disposables. Revenue is recognized over the defined contract term as assays and other disposable products are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Revenue from extended service agreements is deferred and recognized ratably over the term of the agreement. The Company may also be entitled to milestone payments that are contingent upon achieving a predefined objective. The Company follows the milestone method of recognizing revenue from milestones and milestone payments are recorded as revenue in full upon achievement of the milestone. Revenues from royalties related to agreements with strategic partners are recognized when such amounts are reported to the Company; therefore, the underlying end user sales may be related to prior periods. Additional revenue is derived from cost-type contracts with the U.S. government. Revenue and profit under cost-plus service contracts are recognized as costs are incurred, plus negotiated fees. Fixed fees on cost-plus service contracts are recognized ratably over the contract performance period as services are performed. Contract costs include labor and related employee benefits, subcontracting costs and other direct costs, as well as allocations of allowable indirect costs. For contract change orders, claims or similar items, judgment is required for estimating the amounts, assessing the potential for realization, and determining whether realization is probable. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known. Reimbursements of certain costs, including certain hardware costs or out-of-pocket expenses, are included in revenue with corresponding costs included in cost of revenue as costs are incurred. The Company continuously monitors collections and payments from its customers and maintains allowances for doubtful accounts based upon its historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the Company’s expectations, there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts. We adopted new revenue accounting guidance effective January 1, 2018, which will impact the amount and timing of our future revenue recognition. For further discussion, see Note 17, “Recent Accounting Pronouncements”. Product-Related Expenses The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising expenses, which include trade shows and conventions, were approximately $2.4 million , $2.2 million and $2.3 million for 2017 , 2016 and 2015 , respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income. Research and Development Costs Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years. Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material. Incentive Compensation Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized. The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense. Earnings Per Share Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect. Stock-Based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.

RESTRUCTURING (Notes)

RESTRUCTURING (Notes)	12 Months Ended
	Dec. 31, 2017
RESTRUCTURING [Abstract]
Restructuring and Related Costs [Table Text Block]	NOTE 2 — REORGANIZATION Following the acquisition of Nanosphere, Inc. (Nanosphere), and to better focus on the Company's core business, the Company conducted a reorganization in December 2016. The reorganization included a headcount reduction of approximately 40 people, a reallocation of responsibilities within the research and development organization and a significant reduction of biodefense efforts. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits. As a result of the organizational change, the Company eliminated approximately 4% of its aggregate workforce. The Company recognized a charge of approximately $2.5 million in the fourth quarter of 2016 in conjunction with these activities. Rollforward of Accrued Reorganization (in thousands) December 31, 2017 Balance at beginning of year $ 1,471 Total reorganization charges — Employee separation payments (1,471 ) Balance at end of period $ — The reorganization accrual balance was paid in January 2017. As such, there is no remaining liability within accrued liabilities on the consolidated balance sheet as of December 31, 2017 .

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2017
Investments [Abstract]
INVESTMENTS	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates the fair value of these investments. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity. As of December 31, 2017 and December 31, 2016 , all of the Company’s marketable securities were classified as available-for-sale. Marketable securities are recorded as either short-term or long-term on the balance sheet based on the contractual maturity date. The fair value of all securities is determined by quoted market prices, market interest rate inputs, or other than quoted prices that are observable either directly or indirectly (as of the end of the reporting period). Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings. As of December 31, 2017 , the Company had no short or long term investments, since those funds were used to pay for a portion of the acquisition of Nanosphere.

ACCOUNTS RECEIVABLE AND RESERVE

ACCOUNTS RECEIVABLE AND RESERVES	12 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
ACCOUNTS RECEIVABLE AND RESERVES	NOTE 4 — ACCOUNTS RECEIVABLE AND RESERVES The Company records an allowance for doubtful accounts based upon a specific review of all outstanding invoices, known collection issues and historical experience. The Company regularly evaluates the collectability of its trade accounts receivables and performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and its assessment of the customer’s current creditworthiness. These estimates are based on specific facts and circumstances of particular orders, analysis of credit memo data and other known factors. Accounts receivable consisted of the following at December 31 (in thousands): 2017 2016 Accounts receivable $ 41,993 $ 28,181 Accounts receivable acquired through the Nanosphere acquisition — 4,603 Less: Allowance for doubtful accounts (1,345 ) (419 ) $ 40,648 $ 32,365 The following table summarizes the changes in the allowance for doubtful accounts (in thousands): Balance at December 31, 2014 $ 4,357 Recoveries charged to costs and expenses 456 Write-offs of uncollectible accounts (4,609 ) Balance at December 31, 2015 $ 204 Increases charged to costs and expenses 320 Write-offs of uncollectible accounts (105 ) Balance at December 31, 2016 $ 419 Increases charged to costs and expenses 1,312 Write-offs of uncollectible accounts (386 ) Balance at December 31, 2017 $ 1,345

INVENTORIES, NET

INVENTORIES, NET	12 Months Ended
	Dec. 31, 2017
Inventory, Net [Abstract]
INVENTORIES, NET	NOTE 5 — INVENTORIES, NET Inventories consisted of the following at December 31 (in thousands): 2017 2016 Parts and supplies $ 29,266 $ 22,960 Work-in-progress 8,712 6,268 Finished goods 11,500 11,547 $ 49,478 $ 40,775 The Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $31.1 million at December 31, 2017 . Should production requirements fall below the level of the Company’s commitments, the Company could be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 6 — FAIR VALUE MEASUREMENT ASC 820 "Fair Value Measurement" (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2017 . The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016 (in thousands): Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 701 $ — $ — $ 701 Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 701 $ — $ — $ 701

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 7 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following at December 31 (in thousands): 2017 2016 Laboratory equipment $ 52,498 $ 48,334 Leasehold improvements 37,155 34,660 Computer equipment 3,174 3,672 Purchased software 22,056 22,009 Furniture and fixtures 5,842 5,242 Assets on loan/rental 15,741 12,517 Capital lease equipment 962 1,321 137,428 127,755 Less: Accumulated depreciation (79,170 ) (70,380 ) $ 58,258 $ 57,375 Depreciation expense was $13.2 million , $11.5 million , and $9.4 million for the years ended December 31, 2017 , 2016 , and 2015 , respectively.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	NOTE 8 — GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill during the period are as follows (in thousands): 2017 2016 Balance at beginning of year $ 85,481 $ 49,619 Acquisition of Nanosphere — 35,862 Balance at end of year $ 85,481 $ 85,481 The Company's goodwill is not expected to be deductible for tax purposes. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Definite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2016 Balance at December 31, 2015 69,102 7,797 1,652 — 78,551 Completion of IP R&D projects 12,283 11,300 4,012 12,982 40,577 Balance at December 31, 2016 81,385 19,097 5,664 12,982 119,128 Less: accumulated amortization: Accumulated amortization balance at December 31, 2015 (21,646 ) (3,667 ) (756 ) — (26,069 ) Amortization expense (6,491 ) (1,371 ) (356 ) — (8,218 ) Accumulated amortization balance at December 31, 2016 (28,137 ) (5,038 ) (1,112 ) — (34,287 ) Net balance at December 31, 2016 $ 53,248 $ 14,059 $ 4,552 $ 12,982 $ 84,841 Weighted average life (in years) 10 10 10 2017 Balance at December 31, 2016 81,385 19,097 5,664 12,982 119,128 Balance at December 31, 2017 81,385 19,097 5,664 12,982 119,128 Less: accumulated amortization: Accumulated amortization balance at December 31, 2016 (28,137 ) (5,038 ) (1,112 ) — (34,287 ) Amortization expense (6,277 ) (1,999 ) (580 ) — (8,856 ) Accumulated amortization balance at December 31, 2017 (34,414 ) (7,037 ) (1,692 ) — (43,143 ) Net balance at December 31, 2017 $ 46,971 $ 12,060 $ 3,972 $ 12,982 $ 75,985 Weighted average life (in years) 11 10 10 The in-process research and development project is the development of the next generation VERIGENE system, VERIGENE II, which we currently believe will start clinical trials in 2018 and be commercially launched in 2019. The estimated costs to complete this project are between $6.0 million and $8.0 million . The estimated aggregate amortization expense for the next five years and thereafter is as follows (in thousands): 2018 $ 8,666 2019 8,666 2020 8,666 2021 8,307 2022 7,060 Thereafter 21,638 $ 63,003 IPR&D 12,982 $ 75,985

OTHER COMPREHENSIVE (LOSS) INCO

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME	12 Months Ended
	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE 9 — OTHER COMPREHENSIVE (LOSS) INCOME Comprehensive (loss) income represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive (loss) income for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands): Foreign Currency Items Available for Sale Investments Accumulated Other Comprehensive Income Items Balance at December 31, 2016 $ (1,692 ) $ — $ (1,692 ) Other comprehensive loss before reclassifications 1,067 — 1,067 Net current-period other comprehensive loss 1,067 — 1,067 Balance at December 31, 2017 $ (625 ) $ — $ (625 ) There are no tax benefits or expenses related to the other comprehensive loss for the twelve months ended December 31, 2017 .

OTHER ASSETS

OTHER ASSETS	12 Months Ended
	Dec. 31, 2017
Other Assets [Abstract]
OTHER ASSETS	During each of the years ended December 31, 2017 and December 31, 2016 , the Company made a $1.0 million minority interest investment (an aggregate of $2.0 million ) in a private company based in the U.S. that is focused on development of next generation technologies. This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee since the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded. Although we may invest further in this entity over the course of the next several quarters, we do not anticipate our ownership interest to exceed 20% in the short term. During the year ended December 31, 2017 , the Company also entered into a $1.4 million promissory note with the private company, for which it owns an aggregate of $2.0 million interest. The promissory note is payable at the annual interest rate of 1.95%, with a maturity date of five years from the date of issuance. The Company owns a minority interest in another private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012. This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee, as the Company owns less than 20% of the voting equity and the investee is not publicly traded. The Company regularly evaluates the carrying value of cost-method investments for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investments. The primary indicators the Company utilizes to identify these events and circumstances are the investee's ability to remain in business, such as the investee's liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income, net in the Consolidated Statements of Operations. As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, these cost-method investments are classified within Level 3 of the fair value hierarchy. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost-method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical. Other long-term assets consisted of the following at December 31 (in thousands): 2017 2016 Purchased technology rights (net of accumulated amortization of $7,012 and $6,453 in 2017 and 2016, respectively) $ 3,149 $ 3,567 Cost-method investments 3,000 2,000 Notes receivable (1) 1,400 — Other 1,050 1,218 $ 8,599 $ 6,785 (1) During the year ended December 31, 2017 , the Company entered into a promissory note with a private company, for which it owns an aggregate of $2.0 million interest. The promissory note is payable at the annual interest rate of 1.95%, with a maturity date of five years from the date of issuance. For the years ended December 31, 2017 and 2016 , the Company recognized amortization expense related to the amortization of purchased technology rights of approximately $559,000 and $394,000 , respectively. Future amortization expense is estimated to be $430,000 in 2018 , $418,000 in 2019 , $318,000 in 2020 , $285,000 in 2021 , $268,000 in 2022 and $1,430,000 thereafter.

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
ACCRUED LIABILITIES	NOTE 10 — ACCRUED LIABILITIES Accrued liabilities consisted of the following as of December 31 (in thousands): 2017 2016 Compensation and employee benefits $ 18,218 $ 17,229 Income and other taxes 1,070 816 Warranty costs 1,308 675 Dividends payable 2,671 — Other 2,723 4,084 $ 25,990 $ 22,804 Sales of certain of the Company’s systems are subject to a warranty. System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically. The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs at December 31, 2014 $ 488 Warranty expenses (859 ) Accrual for warranty costs 924 Accrued warranty costs at December 31, 2015 553 Warranty expenses (1,322 ) Accrual for warranty costs 1,444 Accrued warranty costs at December 31, 2016 675 Warranty expenses (2,049 ) Accrual for warranty costs 2,682 Accrued warranty costs at December 31, 2017 $ 1,308

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Description	The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $5.9 million in 2017 from 2016 primarily due to releasing valuation allowance of $ 13.5 million against net deferred tax assets of our Canadian and Dutch subsidiaries, releasing valuation allowance of $ 1.0 million against net deferred tax assets of certain state net operating loss carryforwards, and recording increased valuation allowance on the net deferred tax assets of our state net operating loss carryforwards of $ 8.6 million as a result of remeasurement using the new U.S. federal corporate tax rate of 21 %. The Company extended its commitments with its largest customer, LabCorp, and determined that it was more likely than not that Canadian deferred tax assets would be realized based on increased positive income projections. We expect to utilize portions of net operating loss carryforwards before statutory expiration dates based on our income projections in the Netherlands, and thus we determined that it was more likely than not that a portion of the Dutch deferred tax assets would be realized. At December 31, 2017 , the Company had gross federal, state and foreign net operating loss carryforwards of approximately $69.8 million , $389.9 million , and $9.5 million , respectively. These losses expire beginning in 2018 . Federal and state net operating losses of approximately $69.8 million and $389.9 million , respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the "change of ownership" provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $7.6 million , $3.7 million , and $15.4 million , respectively. These credits begin to expire in 2018 , except for approximately $3.4 million which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions. Alternative minimum tax credits of $2.3 million which are potentially subject to refund under the Act have been reflected as deferred tax assets. In addition, the Company has a gross scientific research and experimental developmental pool in Canada of approximately $15.4 million which has an indefinite carryforward period.
INCOME TAXES	NOTE 11 — INCOME TAXES The components of income before income taxes for the years ended December 31 are as follows (in thousands): 2017 2016 2015 Domestic $ 18,436 $ 2,281 $ 7,472 Foreign 18,713 17,334 25,572 Total $ 37,149 $ 19,615 $ 33,044 The components of the (benefit) provision for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands): 2017 2016 2015 Current: Federal $ 3,149 $ 1,545 $ 490 Foreign 295 204 174 State 883 449 58 Total current $ 4,327 $ 2,198 $ 722 Deferred: Federal 14,970 (215 ) (13 ) Foreign (9,267 ) 3,813 (4,422 ) State (2,304 ) 5 (104 ) Total deferred 3,399 3,603 (4,539 ) Total (benefit) provision for income taxes $ 7,726 $ 5,801 $ (3,817 ) The Tax Cuts and Jobs Act (the Tax Act) was enacted on December 22, 2017 making significant reforms to the Internal Revenue Code. The reforms include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017 , transition of U.S. international taxation from a worldwide tax system to a territorial system, and a mandatory one-time transition tax on the deemed repatriation of cumulative foreign earnings as of December 31, 2017 . On December 22, 2017 , Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the implication of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act and provides a one-year measurement period to complete the accounting required under ASC 740. In accordance with SAB 118, the Company has calculated its best estimate of the impact of the Tax Act in its year end income tax provision based on its understanding of the Tax Act and guidance available and as a result has recorded $ 12.6 million as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The provisional amount related to the remeasurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was $ 2.7 million . The provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings was $ 6.7 million . The provisional amount related to withholding taxes on the undistributed earnings of our Canadian subsidiary, as these amounts are no longer permanently reinvested, was $ 3.2 million . Additional work is necessary to conduct a more detailed analysis of historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete. The Company recorded an additional amount of tax liability related to the one-time transition tax of $ 2.7 million , after utilization of certain tax attributes, payable over eight years. The provision for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages): Year Ended December 31, 2017 2016 2015 Statutory tax rate 35.0 % 35.0 % 35.0 % State taxes, net of federal benefit (1.4 )% 1.5 % (0.2 )% Permanent items 0.5 % 9.5 % 0.6 % Effect of foreign operations (5.7 )% (9.0 )% (8.0 )% Research and incentive tax credit generated (4.6 )% (14.3 )% (3.0 )% Valuation allowance (37.6 )% 5.5 % (32.1 )% Income tax reserves 0.5 % 1.3 % (0.5 )% Stock compensation deferred 0.0 % 0.0 % (3.5 )% Remeasurement U.S. deferreds 7.3 % 0.0 % 0.0 % Transition tax 18.1 % 0.0 % 0.0 % Foreign earnings withholding tax 8.6 % 0.0 % 0.0 % Other 0.1 % 0.1 % 0.1 % 20.8 % 29.6 % (11.6 )% The Company accounts for income taxes using the asset and liability method in accordance with ASC 740 "Income Taxes" (ASC 740) . Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands): 2017 2016 Deferred tax assets: Accrued liabilities and other $ 6,444 $ 7,582 Net operating loss and credit carryforwards 67,299 81,404 Deferred revenue 1,541 2,628 Depreciation and amortization 4,071 4,980 Stock compensation and other 5,429 7,673 Gross deferred tax assets 84,784 104,267 Valuation allowance (21,943 ) (27,879 ) Total deferred tax assets $ 62,841 $ 76,388 Deferred tax liabilities: Accrued liabilities and other $ (4,207 ) $ (1,333 ) Depreciation and amortization (20,155 ) (31,631 ) Stock compensation — — Acquired intangibles (927 ) (927 ) Total deferred tax liabilities (25,289 ) (33,891 ) Net deferred tax assets $ 37,552 $ 42,497 The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $5.9 million in 2017 from 2016 primarily due to releasing valuation allowance of $ 13.5 million against net deferred tax assets of our Canadian and Dutch subsidiaries, releasing valuation allowance of $ 1.0 million against net deferred tax assets of certain state net operating loss carryforwards, and recording increased valuation allowance on the net deferred tax assets of our state net operating loss carryforwards of $ 8.6 million as a result of remeasurement using the new U.S. federal corporate tax rate of 21 %. The Company extended its commitments with its largest customer, LabCorp, and determined that it was more likely than not that Canadian deferred tax assets would be realized based on increased positive income projections. We expect to utilize portions of net operating loss carryforwards before statutory expiration dates based on our income projections in the Netherlands, and thus we determined that it was more likely than not that a portion of the Dutch deferred tax assets would be realized. At December 31, 2017 , the Company had gross federal, state and foreign net operating loss carryforwards of approximately $69.8 million , $389.9 million , and $9.5 million , respectively. These losses expire beginning in 2018 . Federal and state net operating losses of approximately $69.8 million and $389.9 million , respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the "change of ownership" provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $7.6 million , $3.7 million , and $15.4 million , respectively. These credits begin to expire in 2018 , except for approximately $3.4 million which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions. Alternative minimum tax credits of $2.3 million which are potentially subject to refund under the Act have been reflected as deferred tax assets. In addition, the Company has a gross scientific research and experimental developmental pool in Canada of approximately $15.4 million which has an indefinite carryforward period. The excess of financial reporting basis over tax basis of the Company's foreign subsidiaries is considered permanently reinvested with the exception of certain earnings of the Canadian subsidiary. The cumulative amount of excess financial reporting basis of the Company's non-U.S. subsidiaries was approximately $7.4 million at December 31, 2017 , $26.6 million at December 31, 2016 and $17.2 million at December 31, 2015 . Since the Company does not intend to permanently reinvest its previously taxed Canadian earnings, it had recorded a deferred tax liability of $3.2 million related to withholding and state income taxes associated with the ultimate repatriation from Canada to the U.S. of these previously taxed earnings. Beginning January 1, 2018, the Tax Act implemented a territorial tax system in the U.S. such that the income earned by the Company’s non-U.S. subsidiaries will be subject to a 100% dividend received deduction. As such, only potential withholding and state income taxes on the non-permanently reinvested earnings have a liability recorded. We have not recognized a deferred tax liability related to withholding taxes on the excess financial reporting basis of our other foreign subsidiaries because the Company currently intends to reinvest earnings of these subsidiaries in operations outside the U.S. and determination of such liability, if any, is dependent on circumstances existing if and when remittance occurs. As of December 31, 2017 and December 31, 2016 , the Company had recorded gross unrecognized tax benefits of approximately $2.7 million and $2.6 million , respectively. All of the unrecognized tax benefits as of December 31, 2017 , if recognized, would impact the effective tax rate. The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense. During the years ended December 31, 2017 and 2016 , the Company recognized approximately $35,400 and $3,000 in tax related interest and penalties, respectively. Reserves for interest and penalties as of December 31, 2017 and 2016 are not significant as the Company has net operating loss carryovers. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2017 2016 Balance at beginning of year $ 2,677 $ 2,184 Additions based on tax positions related to the current year 355 481 Additions for tax positions of prior years — 12 Reductions for tax positions of prior years (103 ) — Lapse of statute of limitations (152 ) — Balance at end of year $ 2,777 $ 2,677 As of December 31, 2017 , there were no unrecognized tax benefits that the Company expects would change significantly over the next 12 months. The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2011 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2012 tax year and make adjustments to these net operating loss carryforwards. We are currently under audit in Canada for the Company’s scientific research and experimental development pool claims for the 2012 through 2013 tax years. We do not expect a material adjustment as a result of the audit. We are not under audit in any other major taxing jurisdictions at this time.

NET INCOME PER SHARE

NET INCOME PER SHARE	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NOTE 12 — NET INCOME PER SHARE The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share data): Year Ended December 31, 2017 2016 2015 Basic: Net income $ 29,423 $ 13,814 $ 36,861 Less: allocation to participating securities (529 ) — — Net income attributable to common stockholders $ 28,894 $ 13,814 $ 36,861 Weighted average common stock outstanding 43,173 42,584 42,091 Net income per share attributable to common stockholders $ 0.67 $ 0.32 $ 0.88 Diluted: Net income $ 29,423 $ 13,814 $ 36,861 Less: allocation to participating securities (529 ) — — Net income attributable to common stockholders $ 28,894 $ 13,814 $ 36,861 Weighted average common stock outstanding 43,173 42,584 42,091 Effect of dilutive securities: stock options and awards 127 429 546 Weighted-average shares used in computing net income per share 43,300 43,013 42,637 Net income per share attributable to common stockholders $ 0.67 $ 0.32 $ 0.86 Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 2,182,000 , 2,017,000 , and 1,252,000 shares for the years ended December 31, 2017 , 2016 and 2015 , respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive. We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.

STOCKHOLDERS' EQUITY, EMPLOYEE

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION	NOTE 13 — STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION Preferred Stock The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2017 and 2016 , there was no preferred stock issued and outstanding. Dividends I n February 2017, the Board of Directors initiated a cash dividend program under which the Company anticipates paying a regular quarterly cash dividend. On February 21, 2017 , May 24, 2017 , September 12, 2017 and December 7, 2017 the Board of Directors declared cash dividends on the Company’s common stock of $0.06 per share, respectively. The dividend declared in February was payable to stockholders of record as of March 24, 2017 and was paid on April 14, 2017 . The dividend declared in May was payable to stockholders of record as of June 23, 2017 and was paid on July 14, 2017 . The dividend declared in September was payable to stockholders of record as of September 22, 2017 and was paid on October 13, 2017 . The dividend declared in December was payable to stockholders of record as of December 22, 2017 and was paid on January 12, 2018 . The Company's current intent is to pay a continuing dividend on a quarterly basis. However, future declaration of dividends is subject to the final determination of the Company's Board of Directors. Stock-Based Compensation At December 31, 2017 , the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Third Amended and Restated 2006 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 25, 2006 and amended at the Company’s Annual Meetings on each of May 21, 2009, May 17, 2012 and May 14, 2015. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan) or the 2001 Broad-Based Stock Option Plan (2001 Plan). In addition, at December 31, 2017 , the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company's Annual Meeting on May 17, 2012 and amended at the Company's Annual Meeting on May 18, 2017. Equity Incentive Plans Under the Company’s Equity Incentive Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted share units (RSUs) and options to purchase shares of common stock. The options, RSAs, and RSUs generally vest in installments over a three to five year period, and the options expire either seven or ten years after the date of grant. Under the Equity Incentive Plan, certain employees of, directors of, and consultants to the Company are eligible to be granted RSAs, RSUs, and options to purchase common stock. The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15% , of their base salary through the purchase of the Company's common stock, discounted by 15% . As of December 31, 2017 , there were approximately 2.4 million shares authorized for future issuance under the Company’s Equity Incentive Plan and approximately 407,000 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below. The Equity Incentive Plan and the ESPP are administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant. Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs. On each of March 22, 2016 and March 10, 2017, the Compensation Committee approved an award of stock options (the “Performance Options”) to the Company’s named executive officers and certain other executives that vest over four years based on achievement of certain operating profit and revenue targets in 2016 and 2017, respectively. The Performance Options have an exercise price equal to the closing market price for the Company’s common stock on the Nasdaq Global Select Market on the date of grant (March 22, 2016 and March 10, 2017, respectively) and expire seven years from the date of grant. The Performance Options were measured over a performance period ending on December 31, 2016 and December 31, 2017, respectively. Following the end of the applicable fiscal year, the Committee will determine the number of Performance Options which remain eligible to vest based upon the level of achievement of an established Company performance goal (the "Company Financial Goal"). If the Company fails to meet the threshold performance for the performance period, no Performance Options will be eligible to vest. Minimum vesting for minimum threshold performance starts at 30% of the target value for the Company Financial Goal. If the Company’s performance exceeds the target performance, the recipient may receive additional Performance Options above the target number, subject to a maximum of 200% of the target award. The Company's financial performance resulted in delivery of 140% and 148% of the number of target Performance Options granted for 2016 and 2017, respectively. The Performance Options that remain eligible to vest after the determination date will vest 25% on each of the first four anniversaries of the grant date. In the event of a change of control of the Company before the end of the performance period, the Performance Options will automatically vest based on the greater of actual achievement of the pro-rated Company Financial Goal as of the date of the change of control or 100% of target performance, as determined by the Committee in its sole discretion. The Performance Options are exercisable into shares of the Company’s common stock. Accounting for Stock Compensation Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options, performance options and market value on the date of grant for RSAs. The fair values of stock and stock options are amortized as compensation expense on a straight-line basis over the vesting period of the grants. In accordance with ASC 718, the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected life is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options and performance options. The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant. The assumptions used are summarized in the following table: 2017 2016 2015 Dividend yield 1.3 % — % — % Expected volatility 0.5 0.5 0.5 Risk-free rate of return 2.0 % 1.4 % 1.6 % Expected life of a 10 year contractual term option 7 years 7 years 7 years Expected life of a 7 year contractual term option 4.87 years 4.87 years 4.87 years Weighted average fair value at grant date $ 6.66 $ 7.86 $ 6.73 As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods. The Company’s stock option activity for the years ended December 31, 2015 , 2016 and 2017 is as follows: Stock Options Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2014 825 $ 18.84 Granted 1,023 15.98 Exercised (129 ) 14.59 Cancelled or expired (27 ) 16.67 Outstanding at December 31, 2015 1,692 $ 17.47 Granted 886 19.21 Exercised (178 ) 18.55 Cancelled or expired (220 ) 17.83 Outstanding at December 31, 2016 2,180 $ 18.06 Granted 1,406 18.08 Exercised (172 ) 16.50 Cancelled or expired (328 ) 18.39 Outstanding at December 31, 2017 3,086 $ 18.10 5.19 $ 5,401 Vested at December 31, 2017 and expected to vest 3,026 $ 18.10 5.18 $ 5,307 Exercisable at December 31, 2017 834 $ 18.24 4.22 $ 1,587 During the years ended December 31, 2017 , 2016 and 2015 , the total exercise intrinsic value of stock options exercised was $0.7 million , $0.6 million and $0.8 million , respectively, and the total fair value of stock options that vested was $12.7 million , $1.6 million and $2.5 million , respectively. Exercise intrinsic value represents the difference between the market value of the Company's common stock at the time of exercise and the price paid by the employee to exercise the options. The Company had $11.1 million of total unrecognized compensation costs related to stock options at December 31, 2017 that are expected to be recognized over a weighted-average period of 2.55 years. The Company’s restricted share activity for the years ended December 31, 2015 , 2016 and 2017 is as follows: Restricted Stock Awards Shares (in thousands) Weighted Average Grant Price Non-vested at December 31, 2014 1,098 $ 19.63 Granted 276 15.95 Vested (349 ) 19.30 Cancelled or expired (190 ) 19.19 Non-vested at December 31, 2015 836 $ 18.66 Granted 301 19.76 Vested (231 ) 19.75 Cancelled or expired (96 ) 18.78 Non-vested at December 31, 2016 810 $ 18.74 Granted 370 18.22 Vested (354 ) 18.74 Cancelled or expired (112 ) 18.84 Non-vested at December 31, 2017 715 $ 18.46 Restricted Stock Units Shares (in thousands) Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Non-vested at December 31, 2014 658 Granted 122 Vested (54 ) Cancelled or expired (224 ) Non-vested at December 31, 2015 501 Granted 99 Vested (83 ) Cancelled or expired (61 ) Non-vested at December 31, 2016 457 Granted 104 Vested (122 ) Cancelled or expired (16 ) Non-vested at December 31, 2017 423 1.05 $ 8,342 Vested at December 31, 2017 and expected to vest 417 1.01 $ 8,219 Exercisable at December 31, 2017 273 0.00 $ 5,391 As of December 31, 2017 , there was $13.5 million of unrecognized compensation cost related to RSAs and RSUs. That cost is expected to be recognized over a weighted average-period of 2.05 years . The total fair value of restricted shares vested during the year ended December 31, 2017 , 2016 and 2015 was $8.8 million , $7.0 million and $8.5 million , respectively. RSAs and RSUs may be granted at the discretion of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2017 , the Company awarded 369,715 shares of RSAs, which had a fair value at the date of grant ranging from $18.04 – $20.80 . During the year ended December 31, 2016 , the Company awarded 301,419 shares of RSAs, which had a fair value at the date of grant ranging from $19.48 – $22.59 . During the year ended December 31, 2015 , the Company awarded 276,271 shares of RSAs, which had a fair value at the date of grant ranging from $15.93 – $16.72 . During the year ended December 31, 2017 , the Company awarded 104,237 shares of RSUs, which had a fair value at the date of grant ranging from $18.04 – $20.80 . During the year ended December 31, 2016 , the Company awarded 99,144 shares of RSUs, which had a fair value at the date of grant ranging from $19.48 – $20.62 . During the year ended December 31, 2015 , the Company awarded 121,802 shares of RSUs, which had a fair value at the date of grant ranging from $15.93 – $16.72 . Compensation under these RSAs and RSUs was charged to expense over the restriction period and amounted to $7.2 million , $7.9 million , and $8.1 million in 2017 , 2016 and 2015 , respectively. There were no significant stock compensation costs capitalized into assets as of December 31, 2017 , 2016 or 2015 . The Company received $2.8 million , $3.3 million and $1.9 million for the exercise of stock options during the years ended December 31, 2017 , 2016 and 2015 , respectively. Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan and 2000 Plan from reserves upon the exercise of stock options and vesting of RSAs. The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands): Year Ended December 31, 2017 2016 2015 Cost of revenue $ 1,561 $ 1,247 $ 975 Research and development 2,039 2,658 2,422 Selling, general and administrative 8,878 7,916 7,458 Stock-based compensation costs reflected in net income $ 12,478 $ 11,821 $ 10,855 Employee Savings Plans and Other Benefit Plans Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2017 , 2016 and 2015 , each employee could contribute a percentage of compensation up to a maximum of $18,000 per year, with the Company matching 50% of each employee’s contributions. Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees. All Canadian employees are eligible to participate in the plan. The Company’s contributions to these plans for 2017 , 2016 and 2015 were $3.8 million , $3.2 million and $2.8 million , respectively. Several of the Company’s Netherlands employees are covered by a defined benefit plan. The cost and total liability to the Company is not material. Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan. Employee Stock Purchase Plan In May 2012, the Company's stockholders approved the ESPP, which provides for the purchase of up to 500,000 shares of the Company's common stock by eligible employees. In May 2017, the Company's stockholders approved an amendment to the ESPP Plan, which increased the shares available under the ESPP by 341,744 shares. The ESPP period is semi-annual and allows participants to purchase the Company's common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. As of December 31, 2017 , 2016 and 2015 , 434,300 shares, 341,844 shares and 260,536 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.5 million , $0.4 million and $0.4 million for 2017 , 2016 and 2015 , respectively. The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions: 2017 Assumptions: Risk-free interest rates 1.07% Expected life 0.5 years Expected volatility .45 Dividend yield 1.3 % Reserved Shares of Common Stock At December 31, 2017 and 2016 , the Company had reserved 6,270,286 and 6,816,465 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2017 : Options and RSUs Outstanding Shares Available for Future Issuance Total Shares Reserved Equity Incentive Plan 3,509,316 2,353,526 5,862,842 ESPP — 407,444 407,444 3,509,316 2,760,970 6,270,286

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 — COMMITMENTS AND CONTINGENCIES Lease Arrangements The Company has operating leases related primarily to its office and manufacturing facilities with original lease periods of up to ten years. Rental and lease expense for these operating leases for the years 2017 , 2016 and 2015 totaled approximately $6.6 million , $5.8 million and $4.7 million , respectively. Minimum annual lease commitments as of December 31, 2017 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands): 2018 $ 5,180 2019 4,584 2020 2,708 2021 1,958 2022 1,461 Thereafter 897 Total $ 16,788 These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above. These amounts are recorded to expense on a straight-line basis over the life of the lease. In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives. Non-Cancellable Purchase Commitments As of December 31, 2017 the Company had approximately $31.1 million in purchase commitments primarily with several of its inventory suppliers as well as other operating commitments. Certain of our supply agreements require purchase and delivery of minimum amounts of components through 2018, and purchases under these arrangements were $1.8 million , $2.6 million and $1.2 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Employment Contracts The Company has entered into employment contracts with certain of its key executives. Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason. Legal Proceedings In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When and if it appears probable in management's judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management's judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.

GUARANTEES

GUARANTEES	12 Months Ended
	Dec. 31, 2017
Guarantees [Abstract]
GUARANTEES	NOTE 15 — GUARANTEES The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 16 — GEOGRAPHIC INFORMATION The table below provides information regarding product revenues and property and equipment, net from the Company’s sales to customers within the United States and in foreign countries for the years ended December 31 (in thousands): Sales to Customers Property and Equipment, net 2017 2016 2015 2017 2016 2015 Domestic $ 256,834 $ 222,706 $ 200,427 $ 54,623 $ 53,283 $ 43,910 Foreign: Europe 20,378 19,211 17,034 809 1,079 1,358 Asia 20,134 20,733 12,794 741 730 429 Canada 4,386 3,738 3,239 2,077 2,274 2,085 Other 4,839 4,251 4,214 8 9 14 $ 306,571 $ 270,639 $ 237,708 $ 58,258 $ 57,375 $ 47,796 The Company's aggregate foreign currency transaction losses of $134,000 , $121,000 and $841,000 were included in determining the consolidated results for the years ended December 31, 2017 , 2016 and 2015 , respectively.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Dec. 31, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 17 — RECENT ACCOUNTING PRONOUNCEMENTS Recently adopted accounting guidance In July 2015, the FASB issued guidance regarding the measurement of inventory. The guidance requires inventory to be measured at the lower of cost and net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company adopted this standard during the quarter ended March 31, 2017, and its adoption did not have any impact on its consolidated financial statements. Recent accounting guidance not yet adopted On January 10, 2018, the FASB issued guidance on the accounting for tax on the global intangible low-taxed income (GILTI) provisions of the Tax Act. The GILTI provisions impose a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The guidance indicates that either accounting for deferred taxes related to GILTI inclusions or to treat any taxes on GILTI inclusions as period cost are both acceptable methods subject to an accounting policy election. Effective the first quarter of 2018, we anticipate the Company will elect to treat any potential GILTI inclusions as a period cost. In January 2017, the FASB issued guidance on intangibles, including goodwill which simplifies how companies calculate goodwill impairments by eliminating Step 2 of the impairment test. The guidance requires companies to compare the fair value of a reporting unit to its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In October 2016, the FASB issued guidance on income taxes which requires companies to recognize the income tax effects of intercompany sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. The guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial position and results of operations. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In August 2016, the FASB issued specific guidance on eight cash flow classification issues that are not currently addressed by current U.S. GAAP and thereby reduce the current diversity in practice. This guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial position and results of operations. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In February 2016, the FASB issued guidance requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. The effective date of the new guidance is for the Company's first quarter of fiscal 2019 and early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is currently evaluating the impact of the adoption of this requirement on its consolidated financial statements, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements except for the addition of the right-of-use asset and a lease liability to the balance sheet. In January 2016, the FASB issued guidance that changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. This guidance also changes certain disclosure requirements and other aspects of current U.S. GAAP. This guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The Company does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements as the only potential impact would be related to the Company's cost-method investments discussed in Note 3 - Investments and Other Assets. In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In doing so, companies will need to use their judgment and make estimates more extensively than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. On July 9, 2015, the FASB voted in favor of delaying the effective date of the new standard by one year, with early adoption permitted as of the original effective date. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The new standard permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The Company has assessed its various revenue streams to identify performance obligations under this guidance and the key aspects of the standard that will impact the Company's revenue recognition process. Based upon the Company's assessment, these standards will impact the timing of the recognition of the Company's royalty revenue as the Company has historically waited until the partners have reported end user sales to recognize royalty revenue. With the implementation of the standard, the Company will record a cumulative adjustment increasing retained earnings, which is estimated to be approximately $10.5 to $10.7 million of royalty revenue. After implementation, estimated royalty revenue will be recorded each quarter on an accrual basis to more closely coincide with the timing of the end user sale by the partner; with reconciliation made upon submission of the royalty report by the partner indicating actual royalties owed in the following quarter. We anticipate this could contribute to an increase days sales outstanding by approximately 10 days solely as a result of the timing of when revenue is recorded, not due to any changes in when payments are received. In addition, the Company will begin recording the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue effective January 1, 2018. This change will not have any impact on top line revenue and the Company does not anticipate any material effects to its revenue categorization.

SELECTED QUARTERLY RESULTS (UNA

SELECTED QUARTERLY RESULTS (UNAUDITED)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	NOTE 18 — SELECTED QUARTERLY RESULTS (UNAUDITED) The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 77,779 $ 76,457 $ 74,136 $ 78,199 Gross profit 52,786 50,061 45,819 50,380 Income (loss) from operations 14,012 7,482 6,529 9,130 Net income (loss) 9,231 5,544 17,613 (2,965 ) Basic income (loss) per common share 0.21 0.13 0.40 (0.07 ) Diluted income (loss) per common share 0.21 0.13 0.40 (0.07 ) Cash dividends per common share 0.06 0.06 0.06 0.06 Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 62,981 $ 64,166 $ 71,221 $ 72,271 Gross profit 44,806 44,921 45,665 44,263 Income from operations 11,801 7,500 4,028 (2,343 ) Net income (1) 8,770 5,653 2,751 (3,360 ) Basic income per common share 0.21 0.13 0.06 (0.08 ) Diluted income per common share 0.21 0.13 0.06 (0.08 ) Cash dividends per common share — — — — (1) Net income in the third quarter of 2017 included an income tax benefit from the release of a portion of the valuation allowance on deferred tax assets in Canada. See Note 11 – Income Taxes. See Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations for further discussion.

DESCRIPTION OF BUSINESS AND S26

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business	Description of Business Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company's proprietary technologies. Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company's end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. The Company primarily serves the diagnostics, pharmaceutical and research industries by marketing products, including the Company's specific testing equipment and assays, to various types of testing laboratories. The Company has a large base of installed systems that has grown primarily from the following: • placements made by customers within the Company's Licensed Technologies Group (LTG), previously referred to as the Company's "Partner Business," which customers either: • license the Company's xMAP technology and develop products that incorporate the Company's xMAP technology into products that they then sell to end users, or • purchase the Company's proprietary xMAP laboratory instrumentation and the Company's proprietary xMAP microspheres and sell xMAP-based assay products and/or xMAP-based testing services, which run on the xMAP instrumentation, and pay a royalty to the Company; • In addition, the Company utilizes a direct sales force that focuses on the sale of molecular diagnostic assays that run on the Company's systems. As of December 31, 2017 , the Company had 73 strategic partners, 53 of which have released commercialized reagent-based products utilizing the Company's technology. Luminex and these partners have sold approximately 14,848 xMAP-based instruments in laboratories worldwide as of December 31, 2017 . The Company's remaining partners are in various stages of development and commercialization of products incorporating our technology. A primary focus for the Company's growth is the development and sale of molecular diagnostic assays utilizing the Company's proprietary MultiCode ® and VERIGENE technologies for use on the Company's installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company's increasing installed base of instruments. Luminex's assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex's assay products are currently focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.
Investments	Investments The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates fair value of these investments. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity. Marketable securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date. The fair value of all securities is determined by obtaining non-binding market prices from the Company's third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair values of financial instruments are determined by obtaining non-binding market prices from the Company's third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, cost-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2017 and 2016 . See Note 6 for further details concerning fair value measurements.
Supplemental Cash Flow Statement Information	Supplemental Cash Flow Statement Information (in thousands) Year Ended December 31, 2017 2016 2015 Cash paid during the period for taxes $ 1,393 $ 385 $ 578 Cash (received) paid during the period for interest and penalties 57 (3 ) 96 Cash paid during the period for Nanosphere debt interest — 391 — Cash paid during the period for Nanosphere debt prepayment penalty — 1,500 — Effect of acquisitions: Fair value of tangible assets acquired — 34,372 — Liabilities assumed — (25,391 ) — Cost in excess of fair value of assets acquired — 35,862 — Acquired identifiable intangible assets — 27,595 — Deferred tax assets, net — 6,989 — In-process research and development — 12,982 — Total purchase price — 92,409 — Less cash and cash equivalents acquired — 24,311 — Net cash paid for business acquisition $ — $ 68,098 $ —
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company’s short-term investments consist of investments in high credit quality financial institutions, non-government sponsored debt securities and corporate issuers. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral. Laboratory Corporation of America (LabCorp) accounted for 20% , 20% and 24% of our total revenues in 2017 , 2016 and 2015 , respectively. Thermo Fisher Scientific Inc. accounted for 15% , 13% and 13% of our total revenues in 2017 , 2016 and 2015 , respectively. No other customer accounted for more than 10% of our total revenues in 2017 , 2016 or 2015 .
Inventories	Inventories Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company's markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company's policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company's assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company's estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be overvalued, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company's operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex xMAP, ARIES ® and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as "Assets on loan/rental."
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, using a two-step impairment process tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2017 . In 2017 and 2016 , the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company's annual test did not result in an impairment charge in 2017 , as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2017 , 2016 or 2015 . Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.
Revenue Recognition and Allowance for Doubtful Accounts	Revenue Recognition and Allowance for Doubtful Accounts Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company's systems. The Company recognizes product revenue at the time the product is shipped provided there is persuasive evidence of an agreement, no right of return exists, the fee is fixed or determinable and collectability is probable. There is no customer right of return in the Company’s sales agreements. If the criteria for revenue recognition are not met at the time of shipment, the revenue is deferred until all criteria are met. The Company may enter into arrangements for system sales that are multiple-element arrangements, including services such as installation and multiple products. When such arrangements include installation, no revenue is generally recognized until installation and delivery is complete. When such arrangements include multiple products, all of the products are generally shipped at the same time. As a result, the Company generally does not need to defer revenue for any undelivered elements. However, in situations where revenue is deferred for an undelivered element, the Company has typically been able to determine the selling price of each deliverable in a multiple-element arrangement based on the price for such deliverable when it is sold separately. The Company provides systems and certain other hardware to customers through reagent rental agreements under which the customers commit to purchasing minimum quantities of disposable products at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for diagnostic assays and other disposables. Revenue is recognized over the defined contract term as assays and other disposable products are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Revenue from extended service agreements is deferred and recognized ratably over the term of the agreement. The Company may also be entitled to milestone payments that are contingent upon achieving a predefined objective. The Company follows the milestone method of recognizing revenue from milestones and milestone payments are recorded as revenue in full upon achievement of the milestone. Revenues from royalties related to agreements with strategic partners are recognized when such amounts are reported to the Company; therefore, the underlying end user sales may be related to prior periods. Additional revenue is derived from cost-type contracts with the U.S. government. Revenue and profit under cost-plus service contracts are recognized as costs are incurred, plus negotiated fees. Fixed fees on cost-plus service contracts are recognized ratably over the contract performance period as services are performed. Contract costs include labor and related employee benefits, subcontracting costs and other direct costs, as well as allocations of allowable indirect costs. For contract change orders, claims or similar items, judgment is required for estimating the amounts, assessing the potential for realization, and determining whether realization is probable. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known. Reimbursements of certain costs, including certain hardware costs or out-of-pocket expenses, are included in revenue with corresponding costs included in cost of revenue as costs are incurred. The Company continuously monitors collections and payments from its customers and maintains allowances for doubtful accounts based upon its historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the Company’s expectations, there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.
Product-Related Expenses	Product-Related Expenses The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising expenses, which include trade shows and conventions, were approximately $2.4 million , $2.2 million and $2.3 million for 2017 , 2016 and 2015 , respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.
Research and Development Costs	Research and Development Costs Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.
Foreign Currency Translation	Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.
Incentive Compensation	Incentive Compensation Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized. The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.
Earnings Per Share	Earnings Per Share Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.

INVESTMENTS Investments, Other

INVESTMENTS Investments, Other than Available-for-Sale Securities (Policies)	12 Months Ended
	Dec. 31, 2017
Schedule of Investments [Abstract]
Investment Holdings, Other than Securities [Table Text Block]	During each of the years ended December 31, 2017 and December 31, 2016 , the Company made a $1.0 million minority interest investment (an aggregate of $2.0 million ) in a private company based in the U.S. that is focused on development of next generation technologies. This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee since the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded. Although we may invest further in this entity over the course of the next several quarters, we do not anticipate our ownership interest to exceed 20% in the short term. During the year ended December 31, 2017 , the Company also entered into a $1.4 million promissory note with the private company, for which it owns an aggregate of $2.0 million interest. The promissory note is payable at the annual interest rate of 1.95%, with a maturity date of five years from the date of issuance. The Company owns a minority interest in another private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012. This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee, as the Company owns less than 20% of the voting equity and the investee is not publicly traded.

DESCRIPTION OF BUSINESS AND S28

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Supplemental Cash Flow Statement Information	Supplemental Cash Flow Statement Information (in thousands) Year Ended December 31, 2017 2016 2015 Cash paid during the period for taxes $ 1,393 $ 385 $ 578 Cash (received) paid during the period for interest and penalties 57 (3 ) 96 Cash paid during the period for Nanosphere debt interest — 391 — Cash paid during the period for Nanosphere debt prepayment penalty — 1,500 — Effect of acquisitions: Fair value of tangible assets acquired — 34,372 — Liabilities assumed — (25,391 ) — Cost in excess of fair value of assets acquired — 35,862 — Acquired identifiable intangible assets — 27,595 — Deferred tax assets, net — 6,989 — In-process research and development — 12,982 — Total purchase price — 92,409 — Less cash and cash equivalents acquired — 24,311 — Net cash paid for business acquisition $ — $ 68,098 $ —

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	12 Months Ended
	Dec. 31, 2017
RESTRUCTURING [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Rollforward of Accrued Reorganization (in thousands) December 31, 2017 Balance at beginning of year $ 1,471 Total reorganization charges — Employee separation payments (1,471 ) Balance at end of period $ —

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Investments [Abstract]
Components of available-for-sale securities	There were no proceeds from the sales of available-for-sale securities for the year ended December 31, 2017 . There were $19.5 million in proceeds from the sales of available-for-sale securities during the year ended December 31, 2016 , which were used to partially fund the acquisition of Nanosphere. Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Consolidated Statement of Comprehensive Income. Net unrealized holding losses on available-for-sale securities were included in accumulated other comprehensive income (loss) as of December 31, 2016 . There were no available-for-sale debt securities as of December 31, 2017 . All of the Company's available-for-sale securities with gross unrealized losses as of December 31, 2016 had been in a loss position for less than 12 months.

ACCOUNTS RECEIVABLE AND RESER31

ACCOUNTS RECEIVABLE AND RESERVES (Tables)	12 Months Ended
	Dec. 31, 2017
Receivables [Abstract]
Components of Accounts Receivable	Accounts receivable consisted of the following at December 31 (in thousands): 2017 2016 Accounts receivable $ 41,993 $ 28,181 Accounts receivable acquired through the Nanosphere acquisition — 4,603 Less: Allowance for doubtful accounts (1,345 ) (419 ) $ 40,648 $ 32,365
Changes in Allowance for Doubtful Accounts	The following table summarizes the changes in the allowance for doubtful accounts (in thousands): Balance at December 31, 2014 $ 4,357 Recoveries charged to costs and expenses 456 Write-offs of uncollectible accounts (4,609 ) Balance at December 31, 2015 $ 204 Increases charged to costs and expenses 320 Write-offs of uncollectible accounts (105 ) Balance at December 31, 2016 $ 419 Increases charged to costs and expenses 1,312 Write-offs of uncollectible accounts (386 ) Balance at December 31, 2017 $ 1,345

INVENTORIES, NET (Tables)

INVENTORIES, NET (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory, Net [Abstract]
Inventory	Inventories consisted of the following at December 31 (in thousands): 2017 2016 Parts and supplies $ 29,266 $ 22,960 Work-in-progress 8,712 6,268 Finished goods 11,500 11,547 $ 49,478 $ 40,775

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016 (in thousands): Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 701 $ — $ — $ 701 Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 701 $ — $ — $ 701

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment consisted of the following at December 31 (in thousands): 2017 2016 Laboratory equipment $ 52,498 $ 48,334 Leasehold improvements 37,155 34,660 Computer equipment 3,174 3,672 Purchased software 22,056 22,009 Furniture and fixtures 5,842 5,242 Assets on loan/rental 15,741 12,517 Capital lease equipment 962 1,321 137,428 127,755 Less: Accumulated depreciation (79,170 ) (70,380 ) $ 58,258 $ 57,375

GOODWILL AND OTHER INTANGIBLE35

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill during the period are as follows (in thousands): 2017 2016 Balance at beginning of year $ 85,481 $ 49,619 Acquisition of Nanosphere — 35,862 Balance at end of year $ 85,481 $ 85,481
Schedule of intangible assets	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Definite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2016 Balance at December 31, 2015 69,102 7,797 1,652 — 78,551 Completion of IP R&D projects 12,283 11,300 4,012 12,982 40,577 Balance at December 31, 2016 81,385 19,097 5,664 12,982 119,128 Less: accumulated amortization: Accumulated amortization balance at December 31, 2015 (21,646 ) (3,667 ) (756 ) — (26,069 ) Amortization expense (6,491 ) (1,371 ) (356 ) — (8,218 ) Accumulated amortization balance at December 31, 2016 (28,137 ) (5,038 ) (1,112 ) — (34,287 ) Net balance at December 31, 2016 $ 53,248 $ 14,059 $ 4,552 $ 12,982 $ 84,841 Weighted average life (in years) 10 10 10 2017 Balance at December 31, 2016 81,385 19,097 5,664 12,982 119,128 Balance at December 31, 2017 81,385 19,097 5,664 12,982 119,128 Less: accumulated amortization: Accumulated amortization balance at December 31, 2016 (28,137 ) (5,038 ) (1,112 ) — (34,287 ) Amortization expense (6,277 ) (1,999 ) (580 ) — (8,856 ) Accumulated amortization balance at December 31, 2017 (34,414 ) (7,037 ) (1,692 ) — (43,143 ) Net balance at December 31, 2017 $ 46,971 $ 12,060 $ 3,972 $ 12,982 $ 75,985 Weighted average life (in years) 11 10 10
Estimated aggregate amortization expense for the next five years and thereafter	The estimated aggregate amortization expense for the next five years and thereafter is as follows (in thousands): 2018 $ 8,666 2019 8,666 2020 8,666 2021 8,307 2022 7,060 Thereafter 21,638 $ 63,003 IPR&D 12,982 $ 75,985

OTHER COMPREHENSIVE (LOSS) IN36

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	12 Months Ended
	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands): Foreign Currency Items Available for Sale Investments Accumulated Other Comprehensive Income Items Balance at December 31, 2016 $ (1,692 ) $ — $ (1,692 ) Other comprehensive loss before reclassifications 1,067 — 1,067 Net current-period other comprehensive loss 1,067 — 1,067 Balance at December 31, 2017 $ (625 ) $ — $ (625 )
Comprehensive Income (Loss) [Table Text Block]

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	12 Months Ended
	Dec. 31, 2017
Other Assets [Abstract]
Components of Other Assets	Other long-term assets consisted of the following at December 31 (in thousands): 2017 2016 Purchased technology rights (net of accumulated amortization of $7,012 and $6,453 in 2017 and 2016, respectively) $ 3,149 $ 3,567 Cost-method investments 3,000 2,000 Notes receivable (1) 1,400 — Other 1,050 1,218 $ 8,599 $ 6,785 (1) During the year ended December 31, 2017 , the Company entered into a promissory note with a private company, for which it owns an aggregate of $2.0 million interest. The promissory note is payable at the annual interest rate of 1.95%, with a maturity date of five years from the date of issuance.

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consisted of the following as of December 31 (in thousands): 2017 2016 Compensation and employee benefits $ 18,218 $ 17,229 Income and other taxes 1,070 816 Warranty costs 1,308 675 Dividends payable 2,671 — Other 2,723 4,084 $ 25,990 $ 22,804
Changes in warranty accrual	The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs at December 31, 2014 $ 488 Warranty expenses (859 ) Accrual for warranty costs 924 Accrued warranty costs at December 31, 2015 553 Warranty expenses (1,322 ) Accrual for warranty costs 1,444 Accrued warranty costs at December 31, 2016 675 Warranty expenses (2,049 ) Accrual for warranty costs 2,682 Accrued warranty costs at December 31, 2017 $ 1,308

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of income before income taxes	The components of income before income taxes for the years ended December 31 are as follows (in thousands): 2017 2016 2015 Domestic $ 18,436 $ 2,281 $ 7,472 Foreign 18,713 17,334 25,572 Total $ 37,149 $ 19,615 $ 33,044
Components of the provision (benefit) for income taxes attributable to continuing operations	The components of the (benefit) provision for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands): 2017 2016 2015 Current: Federal $ 3,149 $ 1,545 $ 490 Foreign 295 204 174 State 883 449 58 Total current $ 4,327 $ 2,198 $ 722 Deferred: Federal 14,970 (215 ) (13 ) Foreign (9,267 ) 3,813 (4,422 ) State (2,304 ) 5 (104 ) Total deferred 3,399 3,603 (4,539 ) Total (benefit) provision for income taxes $ 7,726 $ 5,801 $ (3,817 )
Income tax rate reconciliation	The provision for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages): Year Ended December 31, 2017 2016 2015 Statutory tax rate 35.0 % 35.0 % 35.0 % State taxes, net of federal benefit (1.4 )% 1.5 % (0.2 )% Permanent items 0.5 % 9.5 % 0.6 % Effect of foreign operations (5.7 )% (9.0 )% (8.0 )% Research and incentive tax credit generated (4.6 )% (14.3 )% (3.0 )% Valuation allowance (37.6 )% 5.5 % (32.1 )% Income tax reserves 0.5 % 1.3 % (0.5 )% Stock compensation deferred 0.0 % 0.0 % (3.5 )% Remeasurement U.S. deferreds 7.3 % 0.0 % 0.0 % Transition tax 18.1 % 0.0 % 0.0 % Foreign earnings withholding tax 8.6 % 0.0 % 0.0 % Other 0.1 % 0.1 % 0.1 % 20.8 % 29.6 % (11.6 )%
Deferred tax assets and liabilities	2017 2016 Deferred tax assets: Accrued liabilities and other $ 6,444 $ 7,582 Net operating loss and credit carryforwards 67,299 81,404 Deferred revenue 1,541 2,628 Depreciation and amortization 4,071 4,980 Stock compensation and other 5,429 7,673 Gross deferred tax assets 84,784 104,267 Valuation allowance (21,943 ) (27,879 ) Total deferred tax assets $ 62,841 $ 76,388 Deferred tax liabilities: Accrued liabilities and other $ (4,207 ) $ (1,333 ) Depreciation and amortization (20,155 ) (31,631 ) Stock compensation — — Acquired intangibles (927 ) (927 ) Total deferred tax liabilities (25,289 ) (33,891 ) Net deferred tax assets $ 37,552 $ 42,497
Reconciliation of unrecognized tax benefits	A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2017 2016 Balance at beginning of year $ 2,677 $ 2,184 Additions based on tax positions related to the current year 355 481 Additions for tax positions of prior years — 12 Reductions for tax positions of prior years (103 ) — Lapse of statute of limitations (152 ) — Balance at end of year $ 2,777 $ 2,677

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share data): Year Ended December 31, 2017 2016 2015 Basic: Net income $ 29,423 $ 13,814 $ 36,861 Less: allocation to participating securities (529 ) — — Net income attributable to common stockholders $ 28,894 $ 13,814 $ 36,861 Weighted average common stock outstanding 43,173 42,584 42,091 Net income per share attributable to common stockholders $ 0.67 $ 0.32 $ 0.88 Diluted: Net income $ 29,423 $ 13,814 $ 36,861 Less: allocation to participating securities (529 ) — — Net income attributable to common stockholders $ 28,894 $ 13,814 $ 36,861 Weighted average common stock outstanding 43,173 42,584 42,091 Effect of dilutive securities: stock options and awards 127 429 546 Weighted-average shares used in computing net income per share 43,300 43,013 42,637 Net income per share attributable to common stockholders $ 0.67 $ 0.32 $ 0.86

STOCKHOLDERS' EQUITY, EMPLOYE41

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Stock options activity	The Company’s stock option activity for the years ended December 31, 2015 , 2016 and 2017 is as follows: Stock Options Shares (in thousands) Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2014 825 $ 18.84 Granted 1,023 15.98 Exercised (129 ) 14.59 Cancelled or expired (27 ) 16.67 Outstanding at December 31, 2015 1,692 $ 17.47 Granted 886 19.21 Exercised (178 ) 18.55 Cancelled or expired (220 ) 17.83 Outstanding at December 31, 2016 2,180 $ 18.06 Granted 1,406 18.08 Exercised (172 ) 16.50 Cancelled or expired (328 ) 18.39 Outstanding at December 31, 2017 3,086 $ 18.10 5.19 $ 5,401 Vested at December 31, 2017 and expected to vest 3,026 $ 18.10 5.18 $ 5,307 Exercisable at December 31, 2017 834 $ 18.24 4.22 $ 1,587
Fair value assumptions used for stock-based compensation costs	The assumptions used are summarized in the following table: 2017 2016 2015 Dividend yield 1.3 % — % — % Expected volatility 0.5 0.5 0.5 Risk-free rate of return 2.0 % 1.4 % 1.6 % Expected life of a 10 year contractual term option 7 years 7 years 7 years Expected life of a 7 year contractual term option 4.87 years 4.87 years 4.87 years Weighted average fair value at grant date $ 6.66 $ 7.86 $ 6.73
Restricted shares activity	The Company’s restricted share activity for the years ended December 31, 2015 , 2016 and 2017 is as follows: Restricted Stock Awards Shares (in thousands) Weighted Average Grant Price Non-vested at December 31, 2014 1,098 $ 19.63 Granted 276 15.95 Vested (349 ) 19.30 Cancelled or expired (190 ) 19.19 Non-vested at December 31, 2015 836 $ 18.66 Granted 301 19.76 Vested (231 ) 19.75 Cancelled or expired (96 ) 18.78 Non-vested at December 31, 2016 810 $ 18.74 Granted 370 18.22 Vested (354 ) 18.74 Cancelled or expired (112 ) 18.84 Non-vested at December 31, 2017 715 $ 18.46 Restricted Stock Units Shares (in thousands) Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Non-vested at December 31, 2014 658 Granted 122 Vested (54 ) Cancelled or expired (224 ) Non-vested at December 31, 2015 501 Granted 99 Vested (83 ) Cancelled or expired (61 ) Non-vested at December 31, 2016 457 Granted 104 Vested (122 ) Cancelled or expired (16 ) Non-vested at December 31, 2017 423 1.05 $ 8,342 Vested at December 31, 2017 and expected to vest 417 1.01 $ 8,219 Exercisable at December 31, 2017 273 0.00 $ 5,391
Stock-based compensation costs recognized in consolidated statements of income	The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands): Year Ended December 31, 2017 2016 2015 Cost of revenue $ 1,561 $ 1,247 $ 975 Research and development 2,039 2,658 2,422 Selling, general and administrative 8,878 7,916 7,458 Stock-based compensation costs reflected in net income $ 12,478 $ 11,821 $ 10,855
Reserved shares by plan	The following table summarizes the reserved shares by plan as of December 31, 2017 : Options and RSUs Outstanding Shares Available for Future Issuance Total Shares Reserved Equity Incentive Plan 3,509,316 2,353,526 5,862,842 ESPP — 407,444 407,444 3,509,316 2,760,970 6,270,286
Employee Stock [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value assumptions used for stock-based compensation costs	The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions: 2017 Assumptions: Risk-free interest rates 1.07% Expected life 0.5 years Expected volatility .45 Dividend yield 1.3 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Summary of minimum lease commitments for the next five years	Minimum annual lease commitments as of December 31, 2017 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands): 2018 $ 5,180 2019 4,584 2020 2,708 2021 1,958 2022 1,461 Thereafter 897 Total $ 16,788

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of sales and property and equipment, net by geographical area	The table below provides information regarding product revenues and property and equipment, net from the Company’s sales to customers within the United States and in foreign countries for the years ended December 31 (in thousands): Sales to Customers Property and Equipment, net 2017 2016 2015 2017 2016 2015 Domestic $ 256,834 $ 222,706 $ 200,427 $ 54,623 $ 53,283 $ 43,910 Foreign: Europe 20,378 19,211 17,034 809 1,079 1,358 Asia 20,134 20,733 12,794 741 730 429 Canada 4,386 3,738 3,239 2,077 2,274 2,085 Other 4,839 4,251 4,214 8 9 14 $ 306,571 $ 270,639 $ 237,708 $ 58,258 $ 57,375 $ 47,796

SELECTED QUARTERLY RESULTS (Tab

SELECTED QUARTERLY RESULTS (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 77,779 $ 76,457 $ 74,136 $ 78,199 Gross profit 52,786 50,061 45,819 50,380 Income (loss) from operations 14,012 7,482 6,529 9,130 Net income (loss) 9,231 5,544 17,613 (2,965 ) Basic income (loss) per common share 0.21 0.13 0.40 (0.07 ) Diluted income (loss) per common share 0.21 0.13 0.40 (0.07 ) Cash dividends per common share 0.06 0.06 0.06 0.06 Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 62,981 $ 64,166 $ 71,221 $ 72,271 Gross profit 44,806 44,921 45,665 44,263 Income from operations 11,801 7,500 4,028 (2,343 ) Net income (1) 8,770 5,653 2,751 (3,360 ) Basic income per common share 0.21 0.13 0.06 (0.08 ) Diluted income per common share 0.21 0.13 0.06 (0.08 ) Cash dividends per common share — — — —

DESCRIPTION OF BUSINESS AND S45

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Supplemental Cash Flow Information [Abstract]
Cash paid during the period for taxes	$ 1,393,000	$ 385,000	$ 578,000
Interest Income, Operating		(3,000)
Cash paid during the period for interest and penalties	57,000	391,000	96,000
Business Combination, Acquisition Related Costs	0
Effect of acquisitions:
Gain (Loss) on Extinguishment of Debt	0	1,500,000	0
Fair Value of Assets Acquired	0	34,372,000
Liabilities Assumed	0	(25,391,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	0	35,862,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0	27,595,000
Deferred Tax Assets Liabilities Noncurrent	0	6,989,000
Research and Development in Process	0	12,982,000
Business Combination, Consideration Transferred	0	92,409,000
Cash Acquired from Acquisition	0	24,311,000
Payments to Acquire Businesses, Net of Cash Acquired	$ 0	$ 68,098,000	$ 0
Laboratory Corporation of America (LabCorp) [Member]
Concentration Risk [Line Items]
Percentage of total revenues	20.00%	20.00%	24.00%
Thermo Fisher Scientific, Inc. [Member]
Concentration Risk [Line Items]
Percentage of total revenues	15.00%	13.00%	13.00%
Minimum [Member]
Concentration Risk [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Finite-Lived Intangible Asset, Useful Life	9 years
Maximum [Member]
Concentration Risk [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Finite-Lived Intangible Asset, Useful Life	15 years
Research and Development Expense [Member] | Minimum [Member]
Concentration Risk [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Research and Development Expense [Member] | Maximum [Member]
Concentration Risk [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years

DESCRIPTION OF BUSINESS AND S46

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets [Abstract]
Advertising expenses	$ 2.4	$ 2.2	$ 2.3
LabCorp, including acquired Genzyme Genetics [Member]
Intangible Assets [Line Items]
Concentration Risk, Percentage	20.00%	20.00%	24.00%
Thermo Fisher Scientific, Inc. [Member]
Intangible Assets [Line Items]
Concentration Risk, Percentage	15.00%	13.00%	13.00%

BUSINESS COMBINATIONS (Details)

BUSINESS COMBINATIONS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenue	$ 78,199	$ 74,136	$ 76,457	$ 77,779	$ 72,271	$ 71,221	$ 64,166	$ 62,981	$ 306,571	$ 270,639	$ 237,708
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	0				27,595				0	27,595
Net income	$ (2,965)	$ 17,613	$ 5,544	$ 9,231	$ (3,360)	$ 2,751	$ 5,653	$ 8,770	$ 29,423	$ 13,814	$ 36,861
Common stock, par value (in dollars per share)	$ 0.001				$ 0.001				$ 0.001	$ 0.001
Weighted Average Number of Shares Outstanding, Basic									43,173	42,584	42,091
Earnings Per Share, Diluted	$ (0.07)	$ 0.40	$ 0.13	$ 0.21	$ (0.08)	$ 0.06	$ 0.13	$ 0.21	$ 0.67	$ 0.32	$ 0.86
Weighted Average Number of Shares Outstanding, Diluted									43,300	43,013	42,637
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets									$ 0	$ 35,862

RESTRUCTURING (Details)

RESTRUCTURING (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Number of Positions Eliminated			40
Total Restructuring Charges		$ 0
Employee Separation Payments		(1,471)
Restructuring Reserve	$ 1,471	0	$ 1,471
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent			0.00%
Restructuring Charges		$ 0	$ 2,281	$ 0
Other Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 2,500

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Components of Available-for-sale Securities [Line Items]
Amortized Cost	$ 701	$ 701
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	701	701
Proceeds from Sale of Available-for-sale Securities	19,500
Money Market Funds [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	701	701
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	701	701
Total Current Available-for-sale Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	701	701
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	701	701
Total Non-Current Available-for-sale Securities [Member]
Components of Available-for-sale Securities [Line Items]
Amortized Cost	0	0
Gains in Accumulated Other Comprehensive Income (Loss)	0	0
Losses in Accumulated Other Comprehensive Income (Loss)	0	0
Estimated Fair Value	$ 0	$ 0

ACCOUNTS RECEIVABLE AND RESER50

ACCOUNTS RECEIVABLE AND RESERVES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Accounts receivable, gross	$ 41,993	$ 28,181
Accounts Receivable, Related Parties	0	4,603
Less: Allowance for doubtful accounts	(1,345)	(419)
Accounts receivable, net	40,648	32,365
Allowance for Doubtful Accounts [Roll Forward]
Balance	419	204	$ 4,357
Reductions charged to costs and expenses	1,312	320	456
Write-offs of uncollectible accounts	(386)	(105)	(4,609)
Balance	$ 1,345	$ 419	$ 204

INVENTORIES, NET (Details)

INVENTORIES, NET (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory, Net [Abstract]
Parts and supplies	$ 29,266	$ 22,960
Work-in-progress	8,712	6,268
Finished goods	11,500	11,547
Inventory, net	49,478	$ 40,775
Non-cancelable purchase commitments	$ 31,100

FAIR VALUE MEASUREMENT (Details

FAIR VALUE MEASUREMENT (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Amounts included in asset accounts [Abstract]
Money Market funds	$ 701	$ 701
Fair Value, Inputs, Level 1 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	701	701
Fair Value, Inputs, Level 2 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	0	0
Fair Value, Inputs, Level 3 [Member]
Amounts included in asset accounts [Abstract]
Money Market funds	$ 0	$ 0

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 137,428	$ 127,755
Less: Accumulated amortization and depreciation	(79,170)	(70,380)
Property, plant and equipment, net	58,258	57,375	$ 47,796
Depreciation expense	13,200	11,500	$ 9,400
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	52,498	48,334
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	37,155	34,660
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,174	3,672
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	22,056	22,009
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5,842	5,242
Assets On Loan/Rental [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,741	12,517
Capital Lease Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 962	$ 1,321

GOODWILL AND OTHER INTANGIBLE54

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets [Line Items]
Minimum In-Process Research and Development Expense Estimated	$ 6,000
Maximum In-Process Research and Development Expense Estimated	8,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	0	$ 35,862
Goodwill [Roll Forward]
Balance at beginning of year	85,481	49,619
Balance at end of period	$ 85,481	$ 85,481
Technology, Trade Secrets, and Know-how [Member]
Intangible Assets [Line Items]
Intangible assets, estimated lives	11 years	10 years
Customer Lists and Contracts [Member]
Intangible Assets [Line Items]
Intangible assets, estimated lives	10 years	10 years

GOODWILL AND OTHER INTANGIBLE55

GOODWILL AND OTHER INTANGIBLE ASSETS (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Intangible Assets [Line Items]
Minimum In-Process Research and Development Expense Estimated	$ 6,000
Maximum In-Process Research and Development Expense Estimated	8,000
Finite-Lived Intangible Assets, Future Amortization Expense, In-process Research and Development	12,982
Balance, beginning	119,128	$ 78,551
Completion of In Process Research and Development Project		40,577
Balance, ending	119,128	119,128	$ 78,551
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance	(34,287)	(26,069)
Amortization expense	(8,854)	(8,218)	(3,900)
Accumulated amortization, ending balance	(43,143)	(34,287)	(26,069)
Net balance	75,985	84,841
Finite-Lived Intangible Assets, Net	75,985
Estimated aggregate amortization expense for the next five years and thereafter [Abstract]
2,016	8,666
2,017	8,666
2,018	8,666
2,019	8,307
2,020	7,060
Thereafter	21,638
Total amortization of finite-lived intangibles	63,003
In-process Research and Development [Member]
Intangible Assets [Line Items]
Balance, beginning	12,982	0
Completion of In Process Research and Development Project		12,982
Balance, ending	12,982	12,982	0
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance	0	0
Amortization expense	0	0
Accumulated amortization, ending balance	0	0	0
Net balance	12,982	12,982
Technology, Trade Secrets, and Know-how [Member]
Intangible Assets [Line Items]
Balance, beginning	81,385	69,102
Completion of In Process Research and Development Project		12,283
Balance, ending	81,385	81,385	69,102
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance	(28,137)	(21,646)
Amortization expense	(6,277)	(6,491)
Accumulated amortization, ending balance	(34,414)	(28,137)	(21,646)
Net balance	$ 46,971	$ 53,248
Weighted average life (in years)	11 years	10 years
Customer Lists and Contracts [Member]
Intangible Assets [Line Items]
Balance, beginning	$ 19,097	$ 7,797
Completion of In Process Research and Development Project		11,300
Balance, ending	19,097	19,097	7,797
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance	(5,038)	(3,667)
Amortization expense	(1,999)	(1,371)
Accumulated amortization, ending balance	(7,037)	(5,038)	(3,667)
Net balance	$ 12,060	$ 14,059
Weighted average life (in years)	10 years	10 years
Other Identifiable Intangible Assets [Member]
Intangible Assets [Line Items]
Balance, beginning	$ 5,664	$ 1,652
Completion of In Process Research and Development Project		4,012
Balance, ending	5,664	5,664	1,652
Less: accumulated amortization [Abstract]
Accumulated amortization, beginning balance	(1,112)	(756)
Amortization expense	(580)	(356)
Accumulated amortization, ending balance	(1,692)	(1,112)	$ (756)
Net balance	$ 3,972	$ 4,552
Weighted average life (in years)	10 years	10 years

OTHER COMPREHENSIVE (LOSS) IN56

OTHER COMPREHENSIVE (LOSS) INCOME OTHER COMPREHENSIVE (LOSS) INCOME (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance at December 31, 2016	$ (1,692)
Other comprehensive loss before reclassifications	1,067
Net current-period other comprehensive loss	1,067	$ (396)	$ (552)
Balance at December 31, 2017	(625)	(1,692)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance at December 31, 2016	(1,692)
Other comprehensive loss before reclassifications	1,067
Net current-period other comprehensive loss	1,067
Balance at December 31, 2017	(625)	(1,692)
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Balance at December 31, 2016	0
Other comprehensive loss before reclassifications	0
Net current-period other comprehensive loss	0
Balance at December 31, 2017	$ 0	$ 0

OTHER ASSETS (Details)

OTHER ASSETS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2012
Other Assets [Abstract]
Purchased technology rights (net of accumulated amortization)	$ 3,149,000	$ 3,567,000
Cost-method investments	3,000,000	2,000,000
Notes, Loans and Financing Receivable, Net, Noncurrent	1,400,000	0
Other	1,050,000	1,218,000
Non-current other assets	8,599,000	6,785,000
Amortization expense relating to acquired technology rights	$ 559,000	$ 394,000
Amount of investments in a private company			$ 1,000,000
Significant influence percentage (in hundredths)	20.00%
Estimated future amortization expense [Abstract]
2,016	$ 430,000
2,017	418,000
2,018	318,000
2,019	285,000
2,020	268,000
Thereafter	$ 1,430,000

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Dividends Payable, Current	$ 2,671	$ 0
Accrued Employee Benefits, Current	18,218	17,229
Accrued Income And Other Taxes	1,070	816
Other Accrued Liabilities, Current	2,723	4,084
Accrued Liabilities, Current	25,990	22,804
Accrued warranty costs [Roll Forward]
Accrued warranty costs	675	553	$ 488
Warranty expenses	(2,049)	(1,322)	(859)
Accrual for warranty costs	2,682	1,444	924
Accrued warranty costs	$ 1,308	$ 675	$ 553

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Components of income tax expense (benefit) [Abstract]
Domestic		$ 18,436,000	$ 2,281,000	$ 7,472,000
Foreign		18,713,000	17,334,000	25,572,000
Income before income taxes		37,149,000	19,615,000	33,044,000
Federal		3,149,000	1,545,000	490,000
Foreign		295,000	204,000	174,000
State		883,000	449,000	58,000
Total current		4,327,000	2,198,000	722,000
Deferred [Abstract]
Federal		14,970,000	(215,000)	(13,000)
Foreign		(9,267,000)	3,813,000	(4,422,000)
State		(2,304,000)	5,000	(104,000)
Total deferred		3,399,000	3,603,000	(4,539,000)
Total provision (benefit) for income taxes		$ 7,726,000	$ 5,801,000	$ (3,817,000)
Income tax rate reconciliation [Abstract]
Statutory tax rate (in hundredths)		35.00%	35.00%	35.00%
State taxes, net of federal benefit (in hundredths)		(1.40%)	1.50%	(0.20%)
Permanent items (in hundredths)		0.50%	9.50%	0.60%
Effect of foreign operations (in hundredths)		(5.70%)	(9.00%)	(8.00%)
Research and incentive tax credit generated (in hundredths)		(4.60%)	(14.30%)	(3.00%)
Valuation allowance (in hundredths)		(37.60%)	5.50%	(32.10%)
Income tax reserves (in hundredths)		0.50%	1.30%	(0.50%)
Stock compensation deferred (in hundredths)		(0.00%)	(0.00%)	3.50%
Effective Income Tax Rate Reconciliation, Revaluation of Domestic Deferred Assets and Liabilities		7.30%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Transition Tax		18.10%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Withholdings Tax on Foreign Earnings		8.60%	0.00%	0.00%
Other (in hundredths)		0.10%	0.10%	0.10%
Effective tax rate, excluding amounts recorded for discrete events (in hundredths)		20.80%	29.60%	(11.60%)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent		21.00%
Current deferred tax assets [Abstract]
Accrued liabilities and other	$ 6,444,000	$ 6,444,000	$ 7,582,000
Noncurrent deferred tax assets [Abstract]
Net operating loss and credit carryforwards	67,299,000	67,299,000	81,404,000
Deferred revenue	1,541,000	1,541,000	2,628,000
Depreciation and amortization	4,071,000	4,071,000	4,980,000
Stock compensation	5,429,000	5,429,000	7,673,000
Gross noncurrent deferred tax assets	84,784,000	84,784,000	104,267,000
Valuation allowance	(21,943,000)	(21,943,000)	(27,879,000)
Net noncurrent deferred tax asset	62,841,000	62,841,000	76,388,000
Current deferred tax liabilities [Abstract]
Accrued liabilities and other	(4,207,000)	(4,207,000)	(1,333,000)
Noncurrent deferred tax liabilities [Abstract]
Depreciation and amortization	(20,155,000)	(20,155,000)	(31,631,000)
Stock Compensation	0	0	0
Acquired intangibles	(927,000)	(927,000)	(927,000)
Total noncurrent deferred tax liabilities	25,289,000	25,289,000	33,891,000
Net deferred tax assets	37,552,000	37,552,000	42,497,000
Valuation Allowance [Line Items]
Increase (Decrease) in valuation allowance		5,900,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		13,500,000
Valuation Allowance Deferred Tax Asset Change in Amount, State		1,000,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		8,600,000
Federal net operating losses carry-forwards	69,800,000	69,800,000
Net operating loss carry-forwards, State and local	389,900,000	389,900,000
Foreign non-capital income tax loss carry-forwards	9,500,000	9,500,000
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	15,400,000	$ 15,400,000
Tax Credit Carryforward, Expiration Dates		Dec. 31, 2018
Deferred Tax Assets, Tax Credit Carryforwards, Not Subject to Expiration	3,400,000	$ 3,400,000
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	2,300,000	2,300,000
Undistributed earnings of non-U.S. subsidiaries	7,400,000	7,400,000	26,600,000	$ 17,200,000
Valuation Allowance, Deferred Tax Liability, Change		3,200,000
Unrecognized tax benefits that would impact effective tax rate	2,700,000	2,700,000	2,600,000
Tax related interest and penalties		35,400	3,000
Increase (Decrease) in Income Taxes	12,600,000
Income Tax Examination, Increase (Decrease) in Liability from Prior Year	2,700,000	2,700,000
Foreign Earnings Repatriated	6,700,000
Deferred Tax Liabilities, Undistributed Foreign Earnings	3,200,000	3,200,000
Tax Adjustments, Settlements, and Unusual Provisions	2,700,000
Reconciliation of unrecognized tax benefits [Roll Forward]
Balance, Beginning of period		2,677,000	2,184,000
Additions based on tax positions related to the current year		355,000	481,000
Additions for tax positions of prior years		0	12,000
Reductions for tax positions of prior years		(103,000)	0
Lapse of statute of limitations		(152,000)	0
Balance, End of period	2,777,000	2,777,000	$ 2,677,000	$ 2,184,000
Domestic Country [Member]
Valuation Allowance [Line Items]
Amount of net operating loss acquired in business acquisition	69,800,000	69,800,000
Deferred Tax Assets, Tax Credit Carryforwards	7,600,000	7,600,000
Canada [Member]
Valuation Allowance [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	15,400,000	15,400,000
State and Local Jurisdiction [Member]
Valuation Allowance [Line Items]
Amount of net operating loss acquired in business acquisition	389,900,000	389,900,000
Deferred Tax Assets, Tax Credit Carryforwards	$ 3,700,000	$ 3,700,000

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net income	$ (2,965)	$ 17,613	$ 5,544	$ 9,231	$ (3,360)	$ 2,751	$ 5,653	$ 8,770	$ 29,423	$ 13,814	$ 36,861
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic									(529)	0	0
Net Income (Loss) Available to Common Stockholders, Basic									$ 28,894	$ 13,814	$ 36,861
Denominator:
Weighted Average Number of Shares Outstanding, Basic									43,173,000	42,584,000	42,091,000
Effect of dilutive securities [Abstract]
Stock options and awards (in shares)									127,000	429,000	546,000
Denominator for diluted net income per share - weighted average shares outstanding - diluted (in shares)									43,300,000	43,013,000	42,637,000
Net income per share, basic (in dollars per share)	$ (0.07)	$ 0.40	$ 0.13	$ 0.21	$ (0.08)	$ 0.06	$ 0.13	$ 0.21	$ 0.67	$ 0.32	$ 0.88
Earnings Per Share, Diluted	$ (0.07)	$ 0.40	$ 0.13	$ 0.21	$ (0.08)	$ 0.06	$ 0.13	$ 0.21	$ 0.67	$ 0.32	$ 0.86
Net Income (Loss) Attributable to Parent, Diluted									$ 29,423	$ 13,814	$ 36,861
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted									(529)	0	0
Net Income (Loss) Available to Common Stockholders, Diluted									$ 28,894	$ 13,814	$ 36,861
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive restricted stock awards, stock options									2,182,000	2,017,000	1,252,000

STOCKHOLDERS' EQUITY, EMPLOYE61

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK BASED COMPENSATION (Details)	12 Months Ended
	Dec. 31, 2017shares	Dec. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Board of Directors has the authority to issue preferred stock (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Number of stock-based employee compensation plans	1
Vesting period of options, RSAs, and RSUs, minimum (in years)	3 years
Vesting period of options, RSAs, and RSUs, maximum (in years)	5
Expiration date after date of grant, average (in years)	7 years
Number of shares authorized for future issuance (in shares)	2,760,970
Income From Operation Targets Maximum Performance Target	0.00%
Income From Operations Targets Maximum Performance Target	200.00%
Share-based Compensation Arrangements by Share-based Payment Award, Range of Performance Targets [Domain]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options, RSAs, and RSUs, minimum (in years)	4 years
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for future issuance (in shares)	2,353,526
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage of contribution to ESPP	15.00%
Discount Rate of Common Stock for ESPP	15.00%
Number of shares authorized for future issuance (in shares)	407,444
Number of shares eligible for purchase	407,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date after date of grant, average (in years)	7 years
Expiration date after date of grant, maximum (in years)	10

STOCKHOLDERS' EQUITY, EMPLOYE62

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 0	$ 0	$ 0
Fair value assumptions used [Abstract]
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Expected volatility (in hundredths)	50.00%	50.00%	50.00%
Risk-free rate of return (in hundredths)	2.00%	1.40%	1.60%
Weighted average fair value at grant date (in dollars per share)	$ 6.66	$ 7.86	$ 6.73
Stock options, additional disclosures [Abstract]
Total intrinsic value of stock options exercised	$ 700,000	$ 600,000	$ 800,000
Total fair value of stock options vested	$ 12,700,000	$ 1,600,000	$ 2,500,000
Unrecognized compensation costs, weighted-average period of recognition	2 years 6 months 18 days
Percentage of employer matching contribution (in hundredths)	50.00%	50.00%	50.00%
10 year contractual term option [Member]
Fair value assumptions used [Abstract]
Expected life	7 years	7 years	7 years
7 year contractual term option [Member]
Fair value assumptions used [Abstract]
Expected life	4 years 10 months 15 days	4 years 10 months 15 days	4 years 10 months 15 days
Restricted Stock Units (RSUs) [Member]
Stock options, outstanding [Roll Forward]
Vested and expected to vest, end of period (in shares)	417,000
Exercisable, ending balance (in shares)	273,000
Weighted-average remaining contractual life, outstanding, end of period	1 year 18 days
Weighted-average remaining contractual life, vested and expected to vest, end of period	1 year 4 days
Weighted-average remaining contractual life, exercisable, end of period	0 years
Aggregate intrinsic value, outstanding, end of period	$ 8,342,000
Aggregate intrinsic value, vested and expected to vest, end of period	8,219,000
Aggregate intrinsic value, exercisable, end of period	$ 5,391,000
Equity instruments other than options, nonvested [Roll Forward]
Non-vested, beginning of period (in shares)	457,000	501,000	658,000
Granted (in shares)	104,237	99,144	121,802
Vested (in shares)	(122,000)	(83,000)	(54,000)
Cancelled or expired (in shares)	(16,000)	(61,000)	(224,000)
Non-vested, end of period (in shares)	423,000	457,000	501,000
Stock options, additional disclosures [Abstract]
Grant-date fair value, minimum (in dollars per share)	$ 18.04	$ 19.48	$ 15.93
Grant-date fair value, maximum (in dollars per share)	$ 20.80	$ 20.62	$ 16.72
Restricted Shares [Member]
Stock options, additional disclosures [Abstract]
Total unrecognized compensation costs	$ 13,500,000
Unrecognized compensation costs, weighted-average period of recognition	2 years 18 days
Total fair value of restricted shares vested	$ 8,800,000	$ 7,000,000	$ 8,500,000
Compensation costs charged to expense	$ 7,200,000	$ 7,900,000	$ 8,100,000
Restricted Stock [Member]
Fair value assumptions used [Abstract]
Weighted average fair value at grant date (in dollars per share)	$ 18.46	$ 18.74	$ 18.66	$ 19.63
Equity instruments other than options, nonvested [Roll Forward]
Non-vested, beginning of period (in shares)	810,000	836,000	1,098,000
Granted (in shares)	369,715	301,419	276,271
Vested (in shares)	(354,000)	(231,000)	(349,000)
Cancelled or expired (in shares)	(112,000)	(96,000)	(190,000)
Non-vested, end of period (in shares)	715,000	810,000	836,000
Granted, weighted-average grant-date fair value (in dollars per share)	$ 18.22	$ 19.76	$ 15.95
Vested, weighted-average grant-date fair value (in dollars per share)	18.74	19.75	19.30
Cancelled or expired, weighted-average grant-date fair value (in dollars per share)	18.84	18.78	19.19
Stock options, additional disclosures [Abstract]
Grant-date fair value, minimum (in dollars per share)	18.04	19.48	15.93
Grant-date fair value, maximum (in dollars per share)	$ 20.80	$ 22.59	$ 16.72
Stock Options [Member]
Stock options, outstanding [Roll Forward]
Options outstanding, beginning of period (in shares)	2,180,000	1,692,000	825,000
Granted (in shares)	1,406,000	886,000	1,023,000
Exercised (in shares)	(172,000)	(178,000)	(129,000)
Cancelled or expired (in shares)	(328,000)	(220,000)	(27,000)
Options outstanding, end of period (in shares)	3,086,000	2,180,000	1,692,000
Vested and expected to vest, end of period (in shares)	3,026,000
Exercisable, ending balance (in shares)	834,000
Weighted-average exercise price, end of period (in dollars per share)	$ 18.10	$ 18.06	$ 17.47	$ 18.84
Weighted-average exercise price, granted (in dollars per share)	18.08	19.21	15.98
Weighted average exercise price, exercised (in dollars per share)	16.50	18.55	14.59
Weighted-average exercise price, cancelled or expired (in dollars per share)	18.39	$ 17.83	$ 16.67
Weighted-average exercise price, vested and expected to vest, end of period (in dollars per share)	18.10
Weighted-average exercise price, exercisable, end of period (in dollars per share)	$ 18.24
Weighted-average remaining contractual life, outstanding, end of period	5 years 2 months 8 days
Weighted-average remaining contractual life, vested and expected to vest, end of period	5 years 2 months 5 days
Weighted-average remaining contractual life, exercisable, end of period	4 years 2 months 19 days
Aggregate intrinsic value, outstanding, end of period	$ 5,401,000
Aggregate intrinsic value, vested and expected to vest, end of period	5,307,000
Aggregate intrinsic value, exercisable, end of period	1,587,000
Stock options, additional disclosures [Abstract]
Total unrecognized compensation costs	11,100,000
Proceeds from exercise of stock options	$ 2,800,000	$ 3,300,000	$ 1,900,000
Employee Stock [Member]
Fair value assumptions used [Abstract]
Dividend yield (in hundredths)	1.00%
Expected volatility (in hundredths)	45.00%
Stock options, additional disclosures [Abstract]
Compensation costs charged to expense	$ 500,000	$ 400,000	$ 400,000
Employee Stock [Member] | Minimum [Member]
Fair value assumptions used [Abstract]
Risk-free rate of return (in hundredths)	0.07%
Expected life	4 months 24 days
Employee Stock [Member] | Maximum [Member]
Fair value assumptions used [Abstract]
Risk-free rate of return (in hundredths)	0.08%
Expected life	6 months

STOCKHOLDERS' EQUITY, EMPLOYE63

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 3) - USD ($)	12 Months Ended			36 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Maximum individual contribution to 401(k) plan per year				$ 18,000
Percentage of employer matching contribution (in hundredths)	50.00%	50.00%	50.00%
Employer's contributions to 401(k) and deferred profit sharing plan	$ 3,800,000	$ 3,200,000	$ 2,800,000
Fair value assumptions used [Abstract]
Risk-free rate of return (in hundredths)	2.00%	1.40%	1.60%
Expected volatility (in hundredths)	50.00%	50.00%	50.00%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Preferred Stock, Shares Issued	0	0		0
Preferred Stock, Shares Outstanding	0	0		0
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 1,561,000	$ 1,247,000	$ 975,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	2,039,000	2,658,000	2,422,000
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	8,878,000	7,916,000	7,458,000
Reflected in Net Income (Loss) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	12,478,000	11,821,000	10,855,000
Employee Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 500,000	$ 400,000	$ 400,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000			500,000
Percentage Of Purchase Price Of Common Stock Under ESPP	85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans	434,300	341,844	260,536
Fair value assumptions used [Abstract]
Expected volatility (in hundredths)	45.00%
Dividend yield (in hundredths)	1.00%
Employee Stock [Member] | Minimum [Member]
Fair value assumptions used [Abstract]
Risk-free rate of return (in hundredths)	0.07%
Expected life	4 months 24 days
Employee Stock [Member] | Maximum [Member]
Fair value assumptions used [Abstract]
Risk-free rate of return (in hundredths)	0.08%
Expected life	6 months

STOCKHOLDERS' EQUITY, EMPLOYE64

STOCKHOLDERS' EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION (Details 4) - shares	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options/ warrants outstanding (in shares)	3,509,316
Shares available for future issuance (in shares)	2,760,970
Total shares reserved (in shares)	6,270,286	6,816,465
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options/ warrants outstanding (in shares)	3,509,316
Shares available for future issuance (in shares)	2,353,526
Total shares reserved (in shares)	5,862,842
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options/ warrants outstanding (in shares)	0
Shares available for future issuance (in shares)	407,444
Total shares reserved (in shares)	407,444

COMMITMENTS AND CONTINGENCIES65

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Rental and lease expense	$ 6,600	$ 5,800	$ 4,700
Lease periods maximum (in years)	10
Operating leases future minimum payments due [Abstract]
2,016	$ 5,180
2,017	4,584
2,018	2,708
2,019	1,958
2,020	1,461
Thereafter	897
Total	16,788
Non-cancelable purchase commitments	31,100
Unrecorded Unconditional Purchase Obligation, Purchases	1,800	2,600	1,200
Settlement of litigation	$ 0	$ 0	$ (5,300)

GEOGRAPHIC INFORMATION (Details

GEOGRAPHIC INFORMATION (Details 2) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers	$ 78,199,000	$ 74,136,000	$ 76,457,000	$ 77,779,000	$ 72,271,000	$ 71,221,000	$ 64,166,000	$ 62,981,000	$ 306,571,000	$ 270,639,000	$ 237,708,000
Property and equipment, net	58,258,000				57,375,000				58,258,000	57,375,000	47,796,000
Aggregate foreign currency transaction losses									134,000	121,000	841,000
Domestic Country [Member]
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers									256,834,000	222,706,000	200,427,000
Property and equipment, net	54,623,000				53,283,000				54,623,000	53,283,000	43,910,000
Europe [Member]
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers									20,378,000	19,211,000	17,034,000
Property and equipment, net	809,000				1,079,000				809,000	1,079,000	1,358,000
Asia [Member]
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers									20,134,000	20,733,000	12,794,000
Property and equipment, net	741,000				730,000				741,000	730,000	429,000
Canada [Member]
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers									4,386,000	3,738,000	3,239,000
Property and equipment, net	2,077,000				2,274,000				2,077,000	2,274,000	2,085,000
Other Countries [Member]
Revenues from External Customers and Property and Equipment, net [Line Items]
Revenues from external customers									4,839,000	4,251,000	4,214,000
Property and equipment, net	$ 8,000				$ 9,000				$ 8,000	$ 9,000	$ 14,000

RECENT ACCOUNTING PRONOUNCEME67

RECENT ACCOUNTING PRONOUNCEMENTS Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings	$ 87,655	$ 68,898
Income Tax Expense (Benefit)	$ 7,726	$ 5,801	$ (3,817)

SELECTED QUARTERLY RESULTS (Det

SELECTED QUARTERLY RESULTS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Cost of revenue	$ 27,819	$ 28,317	$ 26,396	$ 24,993	$ 28,008	$ 25,556	$ 19,245	$ 18,175	$ 107,525	$ 90,984	$ 69,001
Operating Expenses	41,250	39,290	42,579	38,774	46,606	41,637	37,421	33,005	161,893	158,669	131,350
Revenue	78,199	74,136	76,457	77,779	72,271	71,221	64,166	62,981	306,571	270,639	237,708
Gross Profit	50,380	45,819	50,061	52,786	44,263	45,665	44,921	44,806	199,046	179,655	168,707
Income from operations	9,130	6,529	7,482	14,012	(2,343)	4,028	7,500	11,801	37,153	20,986	37,357
Net income	$ (2,965)	$ 17,613	$ 5,544	$ 9,231	$ (3,360)	$ 2,751	$ 5,653	$ 8,770	$ 29,423	$ 13,814	$ 36,861
Net income per share, basic (in dollars per share)	$ (0.07)	$ 0.40	$ 0.13	$ 0.21	$ (0.08)	$ 0.06	$ 0.13	$ 0.21	$ 0.67	$ 0.32	$ 0.88
Net income per share, diluted (in dollars per share)	(0.07)	0.40	0.13	0.21	(0.08)	0.06	0.13	0.21	0.67	0.32	0.86
Common Stock, Dividends, Per Share, Declared	$ 0.06	$ 0.06	$ 0.06	$ 0.06	$ 0	$ 0	$ 0	$ 0	$ 240	$ 0	$ 0